[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Tumor antigen,Vaccines,Biomarkers,RNA,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"B. Öven<sup>1<\/sup>, D. Vicente Baz<sup>2<\/sup>, J. Wolf<sup>3<\/sup>, O. Ates<sup>4<\/sup>, E. Göker<sup>5<\/sup>, P. Brück<sup>6<\/sup>, M. Wenger<sup>6<\/sup>, N. Munshi<sup>7<\/sup>, I. Tsyhankova<sup>6<\/sup>, I. Tsyhankova<sup>6<\/sup>, M. Kaczorowska<sup>6<\/sup>, T. Schell<sup>6<\/sup>, J. L. Markman<sup>7<\/sup>, H. Yang<sup>7<\/sup>, Ö. Türeci<sup>6<\/sup>, U. &#350;ahin<sup>6<\/sup>, P. Forde<sup>8<\/sup>, <b>A. Atmaca<\/b><sup>9<\/sup>; <br\/><sup>1<\/sup>Yeditepe University, Istanbul, Turkey, <sup>2<\/sup>Universidad de Sevilla, Sevilla, Spain, <sup>3<\/sup>Universitätsklinikum Köln, Köln, Germany, <sup>4<\/sup>Dr.Abdurrahman Yurtaslan Ankara Onkoloji hospital, Ankara, Turkey, <sup>5<\/sup>Ege University, Izmir, Turkey, <sup>6<\/sup>BioNTech SE, Mainz, Germany, <sup>7<\/sup>BioNTech US, Cambridge, MA, <sup>8<\/sup>Johns Hopkins School of Medicine, Baltimore, MD, <sup>9<\/sup>Krankenhaus Nordwest-University Cancer Center, Frankfurt am Main, Germany","CSlideId":"","ControlKey":"07889b50-eb58-4d58-a09d-1281d5c2887e","ControlNumber":"9929","DisclosureBlock":"&nbsp;<b>B. Öven, <\/b> None..<br><b>D. Vicente Baz, <\/b> None..<br><b>J. Wolf, <\/b> None..<br><b>O. Ates, <\/b> None..<br><b>E. Göker, <\/b> None.&nbsp;<br><b>P. Brück, <\/b> <br><b>BioNTech SE<\/b> Employment. <br><b>M. Wenger, <\/b> <br><b>BioNTech SE<\/b> Employment. <br><b>N. Munshi, <\/b> <br><b>BioNTech US<\/b> Employment. <br><b>I. Tsyhankova, <\/b> <br><b>BioNTech<\/b> Employment. <br><b>I. Tsyhankova, <\/b> <br><b>BioNTech<\/b> Employment. <br><b>M. Kaczorowska, <\/b> <br><b>BioNTech<\/b> Employment. <br><b>T. Schell, <\/b> <br><b>BioNTech SE<\/b> Employment, Stock. <br><b>J. L. Markman, <\/b> <br><b>BioNTech US<\/b> Employment. <br><b>H. Yang, <\/b> <br><b>BioNTech US<\/b> Employment. <br><b>Ö. Türeci, <\/b> <br><b>BioNTech SE<\/b> Other Business Ownership, Other Intellectual Property. <br><b>U. &#350;ahin, <\/b> <br><b>BioNTech SE<\/b> Other Business Ownership, Other Intellectual Property.<br><b>P. Forde, <\/b> None.&nbsp;<br><b>A. Atmaca, <\/b> <br><b>BMS<\/b> Other, Advisory role\/Consulting. <br><b>MSD<\/b> Travel, Other, Advisory role\/Consulting. <br><b>Roche<\/b> Other, Advisory role\/Consulting. <br><b>AstraZeneca<\/b> Other, Advisory role\/Consulting. <br><b>Daiichi-Sankyo<\/b> Travel, Other, Advisory role\/Consulting. <br><b>BioNTech<\/b> Other, Advisory role\/Consulting.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11515","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT051","PresenterBiography":null,"PresenterDisplayName":"Akin Atmaca","PresenterKey":"a3d9da5e-5874-47af-a6de-aae944886ca9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT051. Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen mRNA vaccine BNT116 + docetaxel in patients with advanced non-small cell lung cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Preliminary results from LuCa-MERIT-1, a first-in-human Phase I trial evaluating the fixed antigen mRNA vaccine BNT116 + docetaxel in patients with advanced non-small cell lung cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"NSCLC,Vaccines,Immunotherapy,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D.-T. Chen<\/b><sup>1<\/sup>, J. Sabari<sup>2<\/sup>, J. Thompson<sup>3<\/sup>, J. Niu<sup>4<\/sup>, H. Mamdani<sup>5<\/sup>, R. Thapa<sup>1<\/sup>, Z. Thompson<sup>1<\/sup>, T. Posina<sup>1<\/sup>, A. Ryan<sup>6<\/sup>, R. Venhaus<sup>6<\/sup>, T. Ricciardi<sup>6<\/sup>, K. Ramirez<sup>6<\/sup>, T. Tanvetyanon<sup>1<\/sup>, J. Gray<sup>1<\/sup>; <br\/><sup>1<\/sup>Moffitt Cancer Center, Tampa, FL, <sup>2<\/sup>Laura & Isaac Perlmutter Cancer Center, New York, NY, <sup>3<\/sup>Medical College of Wisconsin, Milwaukee, WI, <sup>4<\/sup>Banner MD Anderson Cancer Center, Gilbert, AZ, <sup>5<\/sup>Karmanos Cancer Institute\/Wayne State University, Detroit, MI, <sup>6<\/sup>Ludwig Institute for Cancer Research, New York, NY","CSlideId":"","ControlKey":"86cfe481-acf8-4952-9b58-d7dec15e3422","ControlNumber":"9786","DisclosureBlock":"&nbsp;<b>D. Chen, <\/b> None..<br><b>J. Sabari, <\/b> None.&nbsp;<br><b>J. Thompson, <\/b> <br><b>AstraZeneca<\/b> honoraria. <br><b>Regeneron<\/b> honoraria. <br><b>GE Healthcare<\/b> honoraria.<br><b>J. Niu, <\/b> None..<br><b>H. Mamdani, <\/b> None..<br><b>R. Thapa, <\/b> None..<br><b>Z. Thompson, <\/b> None..<br><b>T. Posina, <\/b> None..<br><b>A. Ryan, <\/b> None..<br><b>R. Venhaus, <\/b> None..<br><b>T. Ricciardi, <\/b> None..<br><b>K. Ramirez, <\/b> None..<br><b>T. Tanvetyanon, <\/b> None.&nbsp;<br><b>J. Gray, <\/b> <br><b>AbbVie; Spectrum ODAC; Takeda Pharmaceuticals; Triptych Health Partners<\/b> Consultant \/ Advisor. <br><b>AstraZeneca<\/b> Research Support\/ Consultant. <br><b>Blueprint Medicines<\/b> Consultant \/ Advisor. <br><b>Boehringer Ingelheim<\/b> Research Support. <br><b>Bristol-Myers Squibb<\/b> Research Support. <br><b>Daiichi Sankyo, Inc (DSI)<\/b> Consultant \/ Advisor. <br><b>Eli Lilly<\/b> Research Support. <br><b>EMD Serono – Merck KGaA<\/b> Research Support\/Consultant \/ Advisor. <br><b>Genentech<\/b> Research Support. <br><b>Gilead Sciences, Inc<\/b> Consultant \/ Advisor. <br><b>G1 Therapeutics<\/b> Research Support. <br><b>IDEOlogy Health<\/b> Consultant \/ Advisor. <br><b>Janssen Scientific Affairs, LLC<\/b> Consultant \/ Advisor. <br><b>Jazz Pharmaceuticals<\/b> Consultant \/ Advisor. <br><b>Loxo Oncology Inc<\/b> Consultant \/ Advisor. <br><b>Ludwig Institute of Cancer Research<\/b> Research Support. <br><b>Merck & Co., Inc<\/b> Research Support\/ Consultant. <br><b>Novartis<\/b> Research Support\/ Consultant \/ Advisor. <br><b>OncoCyte Biotechnology Company<\/b> Consultant \/ Advisor. <br><b>Pfizer<\/b> Research Support.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11516","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT052","PresenterBiography":null,"PresenterDisplayName":"Dung-Tsa Chen, PhD","PresenterKey":"6abb05ab-537b-4530-99d0-d41e813bce41","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT052. A phase IB study of mRNA-based active cancer vaccine, BI1361849, combined with durvalumab and tremelimumab immunotherapy in patients with non-small cell lung cancer (NSCLC)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase IB study of mRNA-based active cancer vaccine, BI1361849, combined with durvalumab and tremelimumab immunotherapy in patients with non-small cell lung cancer (NSCLC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Lung cancer: non-small cell,Immunotherapy,Biomarkers,T cell,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S. Kim<sup>1<\/sup>, J. Zhang<sup>2<\/sup>, W. Tan<sup>2<\/sup>, H. Yan<sup>3<\/sup>, T. Tian<sup>4<\/sup>, H. Zheng<sup>4<\/sup>, Z. Zhou<sup>2<\/sup>, R. Wang<sup>2<\/sup>, Y. Zhang<sup>3<\/sup>, Z. Shen<sup>3<\/sup>, <b>H. Kim<\/b><sup>5<\/sup>, D. Zhong<sup>6<\/sup>, S. Lu<sup>7<\/sup>; <br\/><sup>1<\/sup>Seoul National University Bundang Hospital, Seongnam, Korea, Republic of, <sup>2<\/sup>BeiGene (Shanghai) Co., Ltd., Shanghai, China, <sup>3<\/sup>BeiGene (Beijing) Co., Ltd., Beijing, China, <sup>4<\/sup>BeiGene USA, Inc., San Mateo, CA, <sup>5<\/sup>Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>6<\/sup>Tianjin Medical University General Hospital, Tianjin, China, <sup>7<\/sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China","CSlideId":"","ControlKey":"a751f8dc-1c91-4449-8314-7e64d7a26560","ControlNumber":"9549","DisclosureBlock":"<b>&nbsp;S. Kim, <\/b> <br><b>Ono Pharmaceutical; Guardant Health; Yuhan; and Janssen Korea Ltd<\/b> Other, Consulting or Advisory Role. <br><b>J. Zhang, <\/b> <br><b>BeiGene (Shanghai) Co., Ltd.<\/b> Employment, Stock, Stock Option. <br><b>W. Tan, <\/b> <br><b>BeiGene (Shanghai) Co., Ltd.<\/b> Employment, Stock, Stock Option, Grant\/Contract, Travel. <br><b>H. Yan, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>T. Tian, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>H. Zheng, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option, Travel. <br><b>Z. Zhou, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>R. Wang, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>Y. Zhang, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>Z. Shen, <\/b> <br><b>BeiGene<\/b> Employment, Stock. <br><b>Ashfield Health<\/b> Independent Contractor, Medical Writing Support, Manuscript Writing. <br><b>H. Kim, <\/b> <br><b>AstraZeneca<\/b> Independent Contractor, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and Data Safety Monitoring Board or Advisory Board. <br><b>Bristol Myers Squibb<\/b> Independent Contractor, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and Data Safety Monitoring Board or Advisory Board. <br><b>MSD<\/b> Independent Contractor, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and Data Safety Monitoring Board or Advisory Board. <br><b>Bayer<\/b> Other, Data Safety Monitoring Board or Advisory Board. <br><b>Takeda<\/b> Other, Data Safety Monitoring Board or Advisory Board. <br><b>Yuhan<\/b> Other, Data Safety Monitoring Board or Advisory Board.<br><b>D. Zhong, <\/b> None.&nbsp;<br><b>S. Lu, <\/b> <br><b>AstraZeneca<\/b> Independent Contractor. <br><b>Pfizer<\/b> Independent Contractor. <br><b>Hutch-Med<\/b> Independent Contractor. <br><b>Zai Lab<\/b> Independent Contractor. <br><b>GenomiCare<\/b> Independent Contractor. <br><b>Yuhan<\/b> Independent Contractor. <br><b>Menarini Group<\/b> Independent Contractor. <br><b>InvestisBio<\/b> Independent Contractor. <br><b>Roche<\/b> Independent Contractor. <br><b>Hansoh Pharma<\/b> Independent Contractor.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11517","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT053","PresenterBiography":null,"PresenterDisplayName":"Hye Ryun Kim, MD, PhD","PresenterKey":"fe4f92f7-0506-4527-a7a2-71c638adccb7","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT053. Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Lung cancer: non-small cell,Cancer progression,Bispecific antibody,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Byoung Chul Cho<\/b><sup>1<\/sup>, Jonathan Goldman<sup>2<\/sup>, Natasha Leighl<sup>3<\/sup>, Filippo De Braud<sup>4<\/sup>, Ki Hyeong Lee<sup>5<\/sup>, François Ghiringhelli<sup>6<\/sup>, Pilar Garrido<sup>7<\/sup>, Julio Peguero<sup>8<\/sup>, Benjamin Besse<sup>9<\/sup>, Philippe Cassier<sup>10<\/sup>, Nicolas Girard<sup>11<\/sup>, Maria de Miguel<sup>12<\/sup>, Rosa Alvarez<sup>13<\/sup>, Alastair Greystroke<sup>14<\/sup>, Yuichiro Ohe<sup>15<\/sup>, Te-Chun Hsia<sup>16<\/sup>, Joshua C. Curtin<sup>17<\/sup>, Sanjib Chowdhury<sup>18<\/sup>, Xuesong Lyu<sup>19<\/sup>, Grace Gao<sup>19<\/sup>, Siyang Qu<sup>19<\/sup>, Patricia Lorenzini<sup>17<\/sup>, Aastha Kapoor<sup>17<\/sup>, Priya Kim<sup>17<\/sup>, Mahadi Baig<sup>20<\/sup>, Meena Thayu<sup>17<\/sup>, Roland E. Knoblauch<sup>17<\/sup>, Sandrine Hiret<sup>21<\/sup>, Pascale Tomasini<sup>22<\/sup><br><br\/><sup>1<\/sup>Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of,<sup>2<\/sup>David Geffen School of Medicine, University of California, Los Angeles, CA,<sup>3<\/sup>Princess Margaret Cancer Centre, Toronto, ON, Canada,<sup>4<\/sup>Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy,<sup>5<\/sup>Chungbuk National University Hospital, Cheongju, Korea, Republic of,<sup>6<\/sup>Institut national de la santé et de la recherche médicale (INSERM) and Cancer Center GF Leclerc, Dijon, France,<sup>7<\/sup>Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain,<sup>8<\/sup>Oncology Consultants, Houston, TX,<sup>9<\/sup>Cancer Medicine Department, Gustave Roussy, Villejuif, France & Paris-Saclay University, Orsay, France,<sup>10<\/sup>Centre Léon Bérard, Lyon, France,<sup>11<\/sup>Institut du Thorax Curie-Montsouris, Paris, France and Paris Saclay University, UVSQ, Versailles, France,<sup>12<\/sup>START-CIOCC Hospital Universitario HM Sanchinarro, Madrid, Spain,<sup>13<\/sup>Gregorio Marañón Hospital, Madrid, Spain,<sup>14<\/sup>Sir Bobby Robson Clinical Trials Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom,<sup>15<\/sup>National Cancer Center Hospital, Tokyo, Japan,<sup>16<\/sup>Division of Pulmonary and Critical Care Medicine, China Medical University Hospital, Taichung, Taiwan,<sup>17<\/sup>Janssen Research & Development, Spring House, PA,<sup>18<\/sup>Janssen Research & Development, Cambridge, MA,<sup>19<\/sup>Janssen Research & Development, Shanghai, China,<sup>20<\/sup>Janssen Research & Development, Raritan, NJ,<sup>21<\/sup>Institut de Cancérologie de l’Ouest-Site René Gauducheau, Saint Herblain, France,<sup>22<\/sup>Hôpitaux Universitaires, de Marseille Timone, France","CSlideId":"","ControlKey":"b2f06007-020e-422e-b2a8-cf719b51524d","ControlNumber":"10444","DisclosureBlock":"<b>&nbsp;B. Cho, <\/b> <br><b>TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp., J INTS BIO<\/b> Stock, Stock Option. <br><b>Champions Oncology, Crown Bioscience, Imagen<\/b> Other Intellectual Property. <br><b>MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, GIInnovation, GI-Cell, Abion, Abbvie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Champions Onoclogy<\/b> Other, Research funding from ineligible companies (PI should disclose even if funding goes to institution). <br><b>CJ bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Janssen, Eli Lilly, MSD, Novartis, Nuvalent, Oncternal, Ono, Regeneron, Dong-A ST, Bridgebio therapeutics, Yuhan<\/b> Other, Research funding from ineligible companies (PI should disclose even if funding goes to institution). <br><b>ImmuneOncia, Illumina, Kanaph therapeutics, Therapex, JINTSbio, Hanmi, CHA Bundang Medical Center<\/b> Other, Research funding from ineligible companies (PI should disclose even if funding goes to institution). <br><b>KANAPH Therapeutic Inc, Bridgebio therapeutics, Cyrus therapeutics, Guardant Health, Oscotec Inc<\/b> Other, Advisory board. <br><b>Abion, BeiGene, Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus therapeutics<\/b> Other, Consultant. <br><b>Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli Lilly, GI-Cell, Guardant, HK Inno-N, Imnewrun Biosciences Inc.<\/b> Other, Consultant. <br><b>Janssen, Takeda, MSD, Janssen, Medpacto, Blueprint medicines, RandBio, Hanmi<\/b> Consultant. <br><b>DAAN Biotherapeutics<\/b> Other, Founder. <br><b>Interpark Bio Convergence Corp.,  J INTS BIO<\/b> Other, Member of the board of directors. <br><b>J. Goldman, <\/b> <br><b>AbbVie, Advaxis, AstraZeneca, BMS, Eli Lilly, Genentech, GSK, Janssen, Merck, Pfizer, Puma, Spectrum, Vaccinex<\/b> Grant\/Contract. <br><b>AbbVie, AstraZeneca, BMS, Genentech, Gilead, Gritstone, Janssen, Jazz, Eli Lilly, Pfizer, Puma, Regeneron<\/b> Other, Consulting Fees. <br><b>N. Leighl, <\/b> <br><b>Merck Sharp & Dohme<\/b> Travel. <br><b>Roche Canada, Guardant Health, MSD, EMD Serono, Eli Lilly, AstraZeneca Canada, Takeda, Amgen, Bayer, MSD Oncology<\/b> Other, Research Funding (Institution). <br><b>F. De Braud, <\/b> <br><b>Nadirex, Dephaforum, Ambrosetti, Incyte, BMS, Motore Sanità, Fare Comunicazione, Itanet, ESO<\/b> Other, Speakers Bureau. <br><b>Sanofi, BMS, Taiho, Incyte<\/b> Other, Advisory Board. <br><b>Pierre Fabre, Mattioli 1885, MCCann Health, MSD, IQVIA<\/b> Other, Consultant. <br><b>K. Hyeong Lee, <\/b> <br><b>Merck Serono<\/b> Grant\/Contract. <br><b>MSD, Pfizer, Eli Lilly, Yuhan, AstraZeneca, BMS<\/b> Other, Consulting Fees.<br><b>F. Ghiringhelli, <\/b> None.&nbsp;<br><b>P. Garrido, <\/b> <br><b>Teva<\/b> Employment. <br><b>Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Boehringer Ingelheim (I); Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH<\/b> Consulting or Advisory Role. <br><b>Gebro Pharma (I); GlaxoSmithKline; IO Biotech; Janssen Biotech (I); Janssen Oncology; Eli Lilly; Merck KGaA<\/b> Consulting or Advisory Role. <br><b>MSD Oncology; Nordic Group (I); Novartis\/Pfizer; Pfizer; Roche Pharma AG; Sanofi\/Regeneron; Takeda<\/b> Consulting or Advisory Role. <br><b>AstraZeneca; BMS; Boehringer Ingelheim; Boehringer Ingelheim (I); Janssen (I); Janssen Oncology; Medscape<\/b> Speakers' Bureau. <br><b>MSD Oncology; Nordic Group (I); Novartis; Pfizer; Roche Pharma AG; Takeda; touchIME<\/b> Speakers' Bureau. <br><b>AstraZeneca Spain<\/b> Travel. <br><b>IO Biotech; Janssen Oncology; Novartis<\/b> Other, Support. <br><b>J. Peguero, <\/b> <br><b>Northwest Medical Specialties<\/b> Employment. <br><b>Northwest Medical Specialties, Quality Cancer Care Alliance<\/b> Other, Leadership. <br><b>Northwest Medical Specialties, All4cure<\/b> Stock, Stock Option. <br><b>Cardinal Health, Novartis, Puma Biotechnology, American Journal of Managed Care<\/b> Other, Honoraria. <br><b>IntegraConnect, Billion to One<\/b> Other, Consulting or Advisory Role. <br><b>Northwest Medical Specialties<\/b> Research Funding. <br><b>Northwest Medical Specialties<\/b> Other, Expert Testimony. <br><b>Northwest Medical Specialties, Quality Cancer Care Alliance<\/b> Travel. <br><b>Northwest Medical Specialties, All4Cure, Quality Cancer Care Alliance, Exigent Research<\/b> Other, Support. <br><b>B. Besse, <\/b> <br><b>4D Pharma, Abbvie, Aptitude Health, Amgen, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celegene<\/b> Other, Funding, Institutional, Financial Interest. <br><b>Cergentis, Cristal Therapeutics, Daiichi-Sankyo, EISAI, Eli Lilly, GSK<\/b> Other, Funding, Institutional, Financial Interest. <br><b>Inivata, IPSEN, Janssen, Onxeo, OSE Immunotherapeutics, Pfizer, Roche-Genentech<\/b> Other, Funding, Institutional, Financial Interest. <br><b>Sanofi, Takeda, Tolero Pharmaceuticals<\/b> Other, Funding, Institutional, Financial Interest. <br><b>Chugai pharmaceutical, Genzyme Corporation, EISAI, Inivata, IPSEN, Turning Point Therapeutics<\/b> Grant\/Contract. <br><b>P. Cassier, <\/b> <br><b>Amgen<\/b> Other, Honoraria. <br><b>Boehringer Ingelheim; Bristol-Myers Squibb\/Celgene; Janssen Oncology; OSE Immunotherapeutics<\/b> Other, Consulting or Advisory Role. <br><b>Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst)<\/b> Other, Research Funding. <br><b>Innate Pharma (Inst); Janssen (Inst); Eli Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)<\/b> Other, Research Funding. <br><b>Plexxikon (Inst); Roche\/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)<\/b> Other, Research Funding. <br><b>OSE Immunotherapeutics; Roche<\/b> Travel. <br><b>N. Girard, <\/b> <br><b>Abbvie, Amgen, AstraZeneca, Beigene, Boehringer  Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Hoffmann-La Roche<\/b> Other, Consulting fees. <br><b>Janssen,  LeoPharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Sivan, Mirati, Pfizer,  Sanofi, Takeda<\/b> Other, Consulting fees. <br><b>Abbvie, Amgen, AstraZeneca, Beigene, Boehringer  Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Hoffmann-La Roche<\/b> Other, Honoraria. <br><b>Janssen,  LeoPharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Sivan, Mirati, Pfizer,  Sanofi, Takeda<\/b> Other, Honoraria. <br><b>Janssen, Amgen, BMS<\/b> Travel. <br><b>Hoffman-La Roche<\/b> Advisory Board. <br><b>M. de Miguel, <\/b> <br><b>Janssen; MSD; Roche<\/b> Other, Honoraria. <br><b>Syneos Health<\/b> Other, Consulting or Advisory Role. <br><b>Abbvie (Inst); Array BioPharma (Inst)<\/b> Other, Research Funding. <br><b>R. Alvarez, <\/b> <br><b>Bristol-Myers Squibb; PharmaMar; Roche\/Genentech<\/b> Other, Honoraria. <br><b>GlaxoSmithKline; Eli Lilly; Novartis; PharmaMar; Roche\/Genentech<\/b> Other, Consulting or Advisory Role. <br><b>AstraZeneca; Bristol-Myers Squibb (Inst); CEBIOTEX (Inst); Janssen Oncology; MSD Oncology (Inst); Novartis; PharmaMar (Inst); Rain Therapeutics; Roche\/Genentech; Takeda (Inst)<\/b> Research Funding. <br><b>PharmaMar; Roche<\/b> Travel.<br><b>A. Greystroke, <\/b> None.&nbsp;<br><b>Y. Ohe, <\/b> <br><b>AstraZeneca, Chugai, Eli Lilly, ONO, BMS,Boehringer Ingelheim, Bayer, Pfizer, MSD, Taiho, Nippon Kayaku, Kyowa Hakko Kirin&#12289;Eisai<\/b> Other, Lecture Fees. <br><b>AstraZeneca, Chugai, Eli Lilly, ONO, BMS, Kyorin, Dainippon- Sumitomo, Pfizer, Taiho, Novartis, Takeda, Kissei, Daiichi-Sankyo, Janssen<\/b> Grant\/Contract.<br><b>T. Hsia, <\/b> None.&nbsp;<br><b>J. C. Curtin, <\/b> <br><b>Janssen<\/b> Employment. <br><b>Johnson & Johnson<\/b> Stock. <br><b>S. Chowdhury, <\/b> <br><b>Janssen<\/b> Employment. <br><b>Johnson & Johnson<\/b> Stock. <br><b>X. Lyu, <\/b> <br><b>Janssen<\/b> Employment. <br><b>Johnson & Johnson<\/b> Stock. <br><b>G. Gao, <\/b> <br><b>Janssen<\/b> Employment. <br><b>Johnson & Johnson<\/b> Stock. <br><b>S. Qu, <\/b> <br><b>Janssen<\/b> Employment. <br><b>Johnson & Johnson<\/b> Stock. <br><b>P. Lorenzini, <\/b> <br><b>Janssen<\/b> Employment. <br><b>Johnson & Johnson<\/b> Stock. <br><b>A. Kapoor, <\/b> <br><b>Janssen<\/b> Employment. <br><b>Johnson & Johnson<\/b> Stock. <br><b>P. Kim, <\/b> <br><b>Janssen<\/b> Employment. <br><b>Johnson & Johnson<\/b> Stock. <br><b>M. Baig, <\/b> <br><b>Janssen<\/b> Employment. <br><b>Johnson & Johnson<\/b> Stock. <br><b>M. Thayu, <\/b> <br><b>Janssen<\/b> Employment. <br><b>Johnson & Johnson<\/b> Stock. <br><b>R. E. Knoblauch, <\/b> <br><b>Janssen<\/b> Employment. <br><b>Johnson & Johnson<\/b> Stock. <br><b>S. Hiret, <\/b> <br><b>AstraZeneca; BMS; Roche; Sanofi; Takeda<\/b> Other, Consulting or Advisory Role. <br><b>Novartis; Roche<\/b> Travel. <br><b>P. Tomasini, <\/b> <br><b>AstraZeneca, Takeda, BMS, Roche, Janssen, Amgen<\/b> Other, Honoraria. <br><b>Takeda, AstraZeneca, BMS<\/b> Travel.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11518","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT054","PresenterBiography":null,"PresenterDisplayName":"Byoung Chul Cho, MD;PhD","PresenterKey":"a3c74de1-80ab-48ea-8bb1-f1dabd1fc3f1","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT054. Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"EGFR,NSCLC,Tyrosine kinase inhibitor,T790M Mutation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>R. Wan<\/b><sup>1<\/sup>, Y. Chau<sup>1<\/sup>, J. Zhao<sup>2<\/sup>, Z. Liu<sup>3<\/sup>, M. Zhao<sup>4<\/sup>, Y. Zhao<sup>5<\/sup>, X. Dai<sup>6<\/sup>, Y. Pan<sup>7<\/sup>, Z. Zhang<sup>8<\/sup>, Y. Yao<sup>9<\/sup>, K. Yang<sup>10<\/sup>, L. Wu<sup>11<\/sup>, Y. Xie<sup>12<\/sup>, B. Chen<sup>13<\/sup>, Y. Yang<sup>14<\/sup>, Y. Guo<sup>15<\/sup>, J. Wang<sup>1<\/sup>, J. Duan<sup>1<\/sup>; <br\/><sup>1<\/sup>Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China, <sup>2<\/sup>Peking University Cancer Hospital, Beijing, China, <sup>3<\/sup>Beijing Chest Hospital, Beijing, China, <sup>4<\/sup>The First Hospital of China Medical University, Shenyang, China, <sup>5<\/sup>The Affiliated Cancer Hospital of Zhengzhou University &   Henan Cancer Hospital, Zhengzhou, China, <sup>6<\/sup>Xuzhou Central Hospital, Xuzhou, China, <sup>7<\/sup>Anhui Provincial Hospital, Hefei, China, <sup>8<\/sup>Anhui Cancer Hospital, Hefei, China, <sup>9<\/sup>The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, <sup>10<\/sup>Wuhan Union Hospital, Wuhan, China, <sup>11<\/sup>Hunan Cancer Hospital, Changsha, China, <sup>12<\/sup>Guangxi Zhuang Autonomous Region People's Hospital, Nanning, China, <sup>13<\/sup>Affiliated Hospital of Xuzhou Medical University, Xuzhou, China, <sup>14<\/sup>Puhe Biopharma Co., Ltd., Beijing, China, <sup>15<\/sup>Puhe Biopharma Co., Ltd, Beijing, China","CSlideId":"","ControlKey":"4f5115d1-2918-485f-8406-d87b2c9a42b2","ControlNumber":"9867","DisclosureBlock":"&nbsp;<b>R. Wan, <\/b> None..<br><b>Y. Chau, <\/b> None..<br><b>J. Zhao, <\/b> None..<br><b>Z. Liu, <\/b> None..<br><b>M. Zhao, <\/b> None..<br><b>Y. Zhao, <\/b> None..<br><b>X. Dai, <\/b> None..<br><b>Y. Pan, <\/b> None..<br><b>Z. Zhang, <\/b> None..<br><b>Y. Yao, <\/b> None..<br><b>K. Yang, <\/b> None..<br><b>L. Wu, <\/b> None..<br><b>Y. Xie, <\/b> None..<br><b>B. Chen, <\/b> None.&nbsp;<br><b>Y. Yang, <\/b> <br><b>Puhe Biopharma Co., Ltd.<\/b> Employment. <br><b>Y. Guo, <\/b> <br><b>Puhe Biopharma Co., Ltd<\/b> Fiduciary Officer.<br><b>J. Wang, <\/b> None..<br><b>J. Duan, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11519","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT055","PresenterBiography":"","PresenterDisplayName":"Rui Wan, MD","PresenterKey":"ec79875d-62b9-4792-a249-ef8c38478d2b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT055. Efficacy of YK-029A, a novel EGFR TKI, in advanced NSCLC patients with acquired T790M mutation<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Efficacy of YK-029A, a novel EGFR TKI, in advanced NSCLC patients with acquired T790M mutation<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Drug resistance,Targeted therapy,RET,Cancer,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"J. Zhong, R. Xiao, W. Xie, M. Chen, X. Chen, H. Wang, Y. Liu, Q. Gao, X. Wang, Z. Wang, Q. Chen, J. Yang, Y. Ji, <b>Y. Wang<\/b>; <br\/>Applied Pharmaceutical Science, Inc, Beijing, China","CSlideId":"","ControlKey":"59e839e0-4b2e-455e-994b-fd111df0d50d","ControlNumber":"10465","DisclosureBlock":"&nbsp;<b>J. Zhong, <\/b> None..<br><b>R. Xiao, <\/b> None..<br><b>W. Xie, <\/b> None..<br><b>M. Chen, <\/b> None..<br><b>X. Chen, <\/b> None..<br><b>H. Wang, <\/b> None..<br><b>Y. Liu, <\/b> None..<br><b>Q. Gao, <\/b> None..<br><b>X. Wang, <\/b> None..<br><b>Z. Wang, <\/b> None..<br><b>Q. Chen, <\/b> None..<br><b>J. Yang, <\/b> None..<br><b>Y. Ji, <\/b> None..<br><b>Y. Wang, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11520","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT056","PresenterBiography":"","PresenterDisplayName":"Yuxun Wang, MD;PhD","PresenterKey":"e707b4a4-487e-40a5-ab89-230d8d1019a7","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT056. Development of a novel next-generation RET inhibitor","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Development of a novel next-generation RET inhibitor","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Malignant melanoma,Targeted therapy,Phase I,Metastatic tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Z. Eroglu<\/b>, V. Yin, J. Markowitz, A. Brohl, A. A. Tarhini, W. Fan, D. De Aquino, A. Chen, U. Rix, N. I. Khushalani, K. Smalley; <br\/>Moffitt Cancer Center, Tampa, FL","CSlideId":"","ControlKey":"59ac3247-892b-4582-8db2-956cc7d6f278","ControlNumber":"10690","DisclosureBlock":"<b>&nbsp;Z. Eroglu, <\/b> <br><b>Regeneron<\/b> Independent Contractor. <br><b>Pfizer<\/b> Independent Contractor. <br><b>Incyte<\/b> Independent Contractor. <br><b>Novartis<\/b> Grant\/Contract. <br><b>Boehringer-Ingelheim<\/b> Grant\/Contract.<br><b>V. Yin, <\/b> None..<br><b>J. Markowitz, <\/b> None..<br><b>A. Brohl, <\/b> None.&nbsp;<br><b>A. A. Tarhini, <\/b> <br><b>Novartis<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract. <br><b>Genentech-Roche<\/b> Grant\/Contract. <br><b>Regeneron<\/b> Grant\/Contract. <br><b>Sanofi-Genzyme<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Nektar<\/b> Grant\/Contract. <br><b>Aegenus<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Other, Advisory board. <br><b>Eisai<\/b> Other, Advisory board.<br><b>W. Fan, <\/b> None..<br><b>D. De Aquino, <\/b> None..<br><b>A. Chen, <\/b> None..<br><b>U. Rix, <\/b> None.&nbsp;<br><b>N. I. Khushalani, <\/b> <br><b>Novartis<\/b> Other, Advisory board.<br><b>K. Smalley, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11521","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT057","PresenterBiography":null,"PresenterDisplayName":"Zeynep Eroglu, MD","PresenterKey":"dd94a084-dbfc-49d8-9efa-f1a2b4d58d60","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT057. Phase 1\/2 trial of trametinib + ceritinib in patients with unresectable melanoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1\/2 trial of trametinib + ceritinib in patients with unresectable melanoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT07-01 Phase I clinical trials in pediatric cancer,,"},{"Key":"Keywords","Value":"Pediatric cancers,Sarcoma\/soft-tissue malignancies,Medulloblastoma,Topoisomerase I inhibitor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"J. Geller<sup>1<\/sup>, P. Thompson<sup>2<\/sup>, J. Oesterheld<sup>3<\/sup>, A. Kim<sup>4<\/sup>, M. McManus<sup>5<\/sup>, <b>J. Bacha<\/b><sup>6<\/sup>, D. M. Brown<sup>6<\/sup>, M. Leggas<sup>7<\/sup>, S. Kanekal<sup>6<\/sup>, N. Sankar<sup>6<\/sup>, L. Lopez<sup>6<\/sup>, N. Yam<sup>6<\/sup>, L. M. Wagner<sup>8<\/sup>; <br\/><sup>1<\/sup>Cincinnati Children’s Hospital Medical Center, University of Cincinnati Department of Pediatrics, Cincinnati, OH, <sup>2<\/sup>UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, <sup>3<\/sup>Levine Children’s Hospital, Charlotte, NC, <sup>4<\/sup>Childrens National Hospital, Washington, DC, <sup>5<\/sup>Sarah Cannon, Nashville, TN, <sup>6<\/sup>Edison Oncology Holding Corp., Menlo Park, CA, <sup>7<\/sup>St. Jude Children’s Research Hospital, Memphis, TN, <sup>8<\/sup>Duke University School of Medicine, Raleigh, NC","CSlideId":"","ControlKey":"a1a8052d-8234-4dae-a221-894ea14c687f","ControlNumber":"10554","DisclosureBlock":"&nbsp;<b>J. Geller, <\/b> None..<br><b>P. Thompson, <\/b> None..<br><b>J. Oesterheld, <\/b> None..<br><b>A. Kim, <\/b> None..<br><b>M. McManus, <\/b> None.&nbsp;<br><b>J. Bacha, <\/b> <br><b>Edison Oncology Holding Corp.<\/b> Independent Contractor, Stock, Stock Option, Other Securities. <br><b>Rakovina Therapeutics Inc.<\/b> Independent Contractor, Stock, Stock Option. <br><b>Sera Biopharma, Inc.<\/b> Independent Contractor, Stock, Stock Option. <br><b>D. M. Brown, <\/b> <br><b>Edison Oncology Holding Corp.<\/b> Independent Contractor, Stock, Stock Option, Other Securities. <br><b>Kintara Therpeutics, Inc.<\/b> Independent Contractor, Stock, Stock Option. <br><b>Rakovina Therapeutics, Inc.<\/b> Other, Board of Directors, Chair Scientific Advisory Board.<br><b>M. Leggas, <\/b> None.&nbsp;<br><b>S. Kanekal, <\/b> <br><b>Edison Oncology Holding Corp.<\/b> Stock Option. <br><b>Kintara Therapeutics, Inc.<\/b> Independent Contractor, Stock Option. <br><b>N. Sankar, <\/b> <br><b>Edison Oncology Holding Corp.<\/b> Independent Contractor, Stock Option. <br><b>L. Lopez, <\/b> <br><b>Edison Oncology Holding Corp.<\/b> Independent Contractor, Stock Option. <br><b>N. Yam, <\/b> <br><b>Edison Oncology Holding Corp.<\/b> Independent Contractor, Stock Option.<br><b>L. M. Wagner, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11522","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT058","PresenterBiography":null,"PresenterDisplayName":"Jeffrey Bacha, BS;MBA","PresenterKey":"ffd64f63-891c-42c7-bbe0-afa1a0ce24d8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT058. A multicenter phase 1-2a clinical study of Orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A multicenter phase 1-2a clinical study of Orotecan (oral irinotecan HCl, VAL-413) in patients with recurrent pediatric solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Sarcoma\/soft-tissue malignancies,ADC,AXL,Phase 1,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>B. A. Van Tine<\/b><sup>1<\/sup>, C. T. Chen<sup>2<\/sup>, V. Moreno<sup>3<\/sup>, E. J. Davis<sup>4<\/sup>, M. J. de Miguel<sup>5<\/sup>, A. Italiano<sup>6<\/sup>, E. Saada-Bouzid<sup>7<\/sup>, M. Milhem<sup>8<\/sup>, C. Valverde<sup>9<\/sup>, S. P. Chawla<sup>10<\/sup>, A. R. Naqash<sup>11<\/sup>, L. Carter<sup>12<\/sup>, R. Jones<sup>13<\/sup>, I. Conti<sup>14<\/sup>, J. Boni<sup>14<\/sup>, K. Havenith<sup>15<\/sup>, Y. LeBruchec<sup>16<\/sup>, S. Pantano<sup>16<\/sup>, J.-Y. Blay<sup>17<\/sup>; <br\/><sup>1<\/sup>Washington University School of Medicine, St. Louis, MO, <sup>2<\/sup>Stanford University School of Medicine, Palo Alto, CA, <sup>3<\/sup>START Madrid-FJD, Fundación Jiménez Díaz, Madrid, Spain, <sup>4<\/sup>Vanderbilt University Medical Center, Nashville, TN, <sup>5<\/sup>START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, Spain, <sup>6<\/sup>Bergonié Institute, Bordeaux, France, <sup>7<\/sup>Université Cote d'Azur, Centre Antoine Lacassagne, Nice, France, <sup>8<\/sup>University of Iowa, Iowa City, IA, <sup>9<\/sup>Vall d'Hebron University Hospital, Barcelona, Spain, <sup>10<\/sup>Sarcoma Oncology Research Center, Santa Monica, CA, <sup>11<\/sup>Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, <sup>12<\/sup>The Christie NHS Foundation Trust, Manchester, United Kingdom, <sup>13<\/sup>Royal Marsden NHS Foundation Trust, London, United Kingdom, <sup>14<\/sup>ADC Therapeutics, New Providence, NJ, <sup>15<\/sup>ADC Therapeutics, London, United Kingdom, <sup>16<\/sup>ADC Therapeutics, Épalinges, Switzerland, <sup>17<\/sup>Centre Léon-Bérard, Lyon, France","CSlideId":"","ControlKey":"99c255cb-389c-42dd-b953-fb59c1d8e532","ControlNumber":"10244","DisclosureBlock":"<b>&nbsp;B. A. Van Tine, <\/b> <br><b>Polaris<\/b> Grant\/Contract, Travel. <br><b>Accuronix Therapeutics<\/b> Patent. <br><b>Deciphera Pharmaceuticals<\/b> Independent Contractor. <br><b>Daiichi Sankyo Inc.<\/b> Independent Contractor, Other, Advisory Board Meeting. <br><b>EcoR1<\/b> Independent Contractor. <br><b>Advenchen<\/b> Travel. <br><b>Putnam\u0009<\/b> Independent Contractor. <br><b>Salarius Pharmaceuticals, Inc.<\/b> Independent Contractor. <br><b>Boxer Capital LLC<\/b> Independent Contractor. <br><b>Acuta Capital Partners, LLC<\/b> Independent Contractor. <br><b>Aadi Biosciences<\/b> Independent Contractor. <br><b>Race Oncology<\/b> Independent Contractor. <br><b>Hinge Bio, Inc.\u0009<\/b> Independent Contractor. <br><b>Kronos Bio, Inc<\/b> Independent Contractor, Travel. <br><b>Sonata Therapeutics, INc.<\/b> Independent Contractor. <br><b>Iterion Therapeutics, Inc.<\/b> Other, honoraria- interview. <br><b>Total Health Conference.<\/b> Travel. <br><b>Adaptimmune<\/b> Travel. <br><b>Epizyme<\/b> Independent Contractor, Other, Attended and Ab Board Meeting. <br><b>Bayer US Medical Affairs Oncology, Boehringer Ingelheim, Agenus, Regeneron Pharmaceuticals ,Curis, Inhibrx<\/b> Other, Attended and Ab Board Meeting. <br><b>C. T. Chen, <\/b> <br><b>Boxer Capital<\/b> Other, consulting\/advisory role. <br><b>Guidepoint Global<\/b> Other, consulting\/advisory role. <br><b>ADC Therapeutics<\/b> Other, Research Funding. <br><b>Gilead<\/b> Other, Research Funding. <br><b>Kinnate Biopharma<\/b> Other, Research Funding. <br><b>Mersana Therapeutics<\/b> Other, Research Funding. <br><b>ORIC Pharmaceuticals<\/b> Other, Research Funding. <br><b>Palleon<\/b> Other, Research Funding. <br><b>Rain Oncology<\/b> Other, Research Funding. <br><b>Riboscience<\/b> Other, Research Funding. <br><b>Takeda<\/b> Other, Research Funding. <br><b>V. Moreno, <\/b> <br><b>Affimed Therapeutics<\/b> Other, consulting\/advisory role. <br><b>AstraZeneca<\/b> Other, consulting\/advisory role, Research Funding. <br><b>Basilea<\/b> Other, consulting\/advisory role. <br><b>Bayer<\/b> Other, consulting\/advisory role, Speakers' Bureau, Research Funding. <br><b>Bristol-Myers Squibb<\/b> Other, consulting\/advisory role, research funding. <br><b>Janssen Oncology<\/b> Other, consulting\/advisory role. <br><b>Merck<\/b> Other, Consulting\/advisory role. <br><b>Roche<\/b> Other, Consulting\/advisory role, Research Funding. <br><b>Pierre Fabre<\/b> Other, Speakers’ Bureau. <br><b>Medscape\/Bayer<\/b> Other, Expert Testimony. <br><b>Nanobiotix<\/b> Other, Expert Testimony. <br><b>AbbVie<\/b> Other, Research Funding. <br><b>ACEA Biosciences<\/b> Other, Research Funding. <br><b>Adaptimmune, Amgen<\/b> Other, Research Funding. <br><b>BeiGene<\/b> Other, Research Funding. <br><b>Boehringer Ingelheim<\/b> Other, Research Funding. <br><b>Celgene<\/b> Other, Research Funding. <br><b>Eisai<\/b> Other, Research Funding. <br><b>E-therapeutics<\/b> Other, Research FUnding. <br><b>GlaxoSmithKline, Janssen, Menarini, Merck, Nanobiotix, Novartis, Pfizer, PharmaMar, PsiOxus Therapeutics, Puma Biotechnology, Regeneron, RigonTEC, Roche, Sanofi, Sierra Oncology, Synthon, Taiho Pharm<\/b> Other, Research Funding. <br><b>E. J. Davis, <\/b> <br><b>Deciphera Pharmaceuticals<\/b> Other, Advisory Board. <br><b>Aadi Bioscience<\/b> Other, Advisory Board. <br><b>Cogent Biosciences<\/b> Other, Research funding to institution for clinical trial. <br><b>Inhibrx<\/b> Research funding to institution for clinical trial. <br><b>Cornerstone Pharmaceuticals<\/b> Other, Research funding to institution for clinical trial.<br><b>M. J. de Miguel, <\/b> None.&nbsp;<br><b>A. Italiano, <\/b> <br><b>Bristol Myers Squibb<\/b> Grant\/Contract. <br><b>Merck Sharp & Dohme<\/b> Grant\/Contract. <br><b>Bayer<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract. <br><b>Novartis<\/b> Grant\/Contract. <br><b>Ipsen<\/b> Grant\/Contract. <br><b>Parthenon<\/b> Grant\/Contract. <br><b>ADC Therapeutics<\/b> Grant\/Contract. <br><b>Lilly<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>E. Saada-Bouzid, <\/b> <br><b>Merck Serono<\/b> Independent Contractor, Grant\/Contract, Travel. <br><b>Merck Sharp & Dohme<\/b> Independent Contractor, Travel.<br><b>M. Milhem, <\/b> None.&nbsp;<br><b>C. Valverde, <\/b> <br><b>Boxer Capital<\/b> Other, Consulting\/advisory role. <br><b>Pharmamar<\/b> Other, Consulting\/advisory role, Research Funding. <br><b>Bayer<\/b> Other, Consulting\/advisory role, Research Funding, Travel or assistance to congress. <br><b>Deciphera Pharmaceuticals<\/b> Other, Consulting\/advisory role, Research Funding. <br><b>Boehringer Ingelheim<\/b> Other, Consulting\/advisory role, Research Funding. <br><b>Roche<\/b> Other, Consulting\/advisory role, Research Funding. <br><b>Novartis<\/b> Other, Research Funding. <br><b>Pfizer<\/b> Other, Research Funding. <br><b>Bristol Myers Squibb<\/b> Other, Research Funding. <br><b>Monopar Therapeutics<\/b> Other, Research Funding. <br><b>Adaptimmune Therapeutics<\/b> Other, Research Funding. <br><b>GSK<\/b> Other, Research Funding. <br><b>AROG Pharmaceuticals<\/b> Research Funding. <br><b>Blueprint Medicines<\/b> Other, Research Funding. <br><b>Philogen<\/b> Other, Research Funding. <br><b>Grupo Español de Investigación en Sarcomas (GEIS)<\/b> Other, Non-remunerated leadership role. <br><b>European Society for Medical Oncology (ESMO)<\/b> Other, Non-remunerated leadership role. <br><b>Sociedad Espanola de Oncologia Medica (SEOM)<\/b> Other, Non-remunerated leadership role. <br><b>American Society of Clinical Oncology (ASCO)<\/b> Other, Non-remunerated leadership role. <br><b>European Organisation for Research and Treatment of Cancer (EORTC)<\/b> Other, Non-remunerated membership or affiliation. <br><b>S. P. Chawla, <\/b> <br><b>Advenchen Laboratories<\/b> Other, Consulting\/advisory role, Honoraria, Research funding. <br><b>Amgen<\/b> Other, Consulting\/advisory role, Honoraria, Research funding, Speakers' Bureau. <br><b>Bayer<\/b> Other, Consulting\/advisory role, Honoraria, Research funding. <br><b>CytRx<\/b> Other, Consulting\/advisory role, Honoraria, Research funding, Speakers' Bureau. <br><b>GlaxoSmithKline<\/b> Other, Consulting\/advisory role, Honoraria, Research funding, Speakers' Bureau. <br><b>Ignyta<\/b> Other, Consulting\/advisory role, Honoraria, Research funding, Speakers' Bureau. <br><b>Immune design<\/b> Other, Consulting\/advisory role, Honoraria, Research funding, Speakers' Bureau. <br><b>InhibRx<\/b> Other, Consulting\/advisory role, Honoraria, Research funding. <br><b>Jassen<\/b> Other, Consulting\/advisory role, Honoraria, Research funding, Speakers' Bureau. <br><b>NKMax<\/b> Other, Consulting\/advisory role, Honoraria, Research funding. <br><b>Roche<\/b> Other, Consulting\/advisory role, Honoraria, Research funding, Speakers' Bureau. <br><b>Sarc<\/b> Other, Consulting\/advisory role, Honoraria, Research funding, Speakers' Bureau. <br><b>Threshold Pharmaceuticals<\/b> Other, Consulting\/advisory role, Honoraria, Research funding, Speakers' Bureau. <br><b>TRACON Pharma<\/b> Other, Consulting\/advisory role, Honoraria, Research funding, Speakers' Bureau. <br><b>Aadi<\/b> Stock, Stock. <br><b>Cellestia Biotech<\/b> Stock, Stock. <br><b>Immix BioPharma<\/b> Stock, Stock. <br><b>Tyme<\/b> Honoraria, Honoraria. <br><b>A. R. Naqash, <\/b> <br><b>Loxo@Lilly<\/b> Other, Funding to Institution for Trials. <br><b>Surface Oncology<\/b> Other, Funding to Institution for Trials. <br><b>ADC Therapeutics<\/b> Other, Funding to Institution for Trials. <br><b>IGM Biosciences<\/b> Other, Funding to Institution for Trials. <br><b>EMD Serono<\/b> Other, Funding to Institution for Trials\u000d\u000a. <br><b>Aravive<\/b> Other, Funding to Institution for Trials. <br><b>Nikang Therapeutics<\/b> Other, Funding to Institution for Trials. <br><b>Inspirna<\/b> Other, Funding to Institution for Trials. <br><b>Exelexis<\/b> Other, Funding to Institution for Trials. <br><b>Revolution Medicine<\/b> Other, Funding to Institution for Trials. <br><b>Jacobio Pharma<\/b> Other, Funding to Institution for Trials. <br><b>Pionyr Immunotherapeutics<\/b> Other, Funding to Institution for Trials. <br><b>Jazz Pharmaceuticals<\/b> Other, Funding to Institution for Trials\u000d\u000aTravel compensation. <br><b>NGM Biopharmaceuticals<\/b> Other, Funding to Institution for Trials. <br><b>Immunophotonics<\/b> Other, Funding to Institution for Trials. <br><b>Selexine<\/b> Other, Funding to Institution for Trials. <br><b>JCO Precision Oncology<\/b> Other, Consultant Editor Compensation. <br><b>Society for Immunotherapy of Cancer (SITC), American Association for Cancer Research (AACR), Conquer Cancer Foundation, BinayTara Foundation, Caris Life Sciences<\/b> Other, Travel compensation. <br><b>Foundation Medicine<\/b> Other, Advisory Board\u000d\u000aTravel compensation. <br><b>SWOG Hope Foundation, FDA Broad Agency<\/b> Grant\/Contract.<br><b>L. Carter, <\/b> None.&nbsp;<br><b>R. Jones, <\/b> <br><b>Merck Sharp & Dohme<\/b> Grant\/Contract, Other, Research Funding. <br><b>GSK<\/b> Grant\/Contract, Other, Research Funding. <br><b>Adaptimmune<\/b> Other, Consulting. <br><b>Astex Pharmaceuticals<\/b> Other, Consulting. <br><b>Athenex<\/b> Other, Consulting. <br><b>Bayer<\/b> Other, Consulting. <br><b>Boehringer Ingelheim<\/b> Other, Consulting. <br><b>Blueprint Medicines<\/b> Other, Consulting. <br><b>Clinigen<\/b> Other, Consulting. <br><b>Eisai<\/b> Other, Consulting. <br><b>Epizyme<\/b> Other, Consulting. <br><b>Daichii<\/b> Other, Consulting. <br><b>Deciphera Pharmaceuticals<\/b> Other, Consulting. <br><b>Immunedesign<\/b> Other, Consulting. <br><b>Immunicum<\/b> Other, Consulting. <br><b>Karma Oncology<\/b> Other, Consulting. <br><b>Lilly<\/b> Other, Consulting. <br><b>Merck<\/b> Other, Consulting. <br><b>Mundipharma<\/b> Other, Consulting. <br><b>Pharmamar, Springworks, SynOx Therapeutics, Tracon, UpToDate<\/b> Other, Consulting. <br><b>I. Conti, <\/b> <br><b>ADC Therapeutics<\/b> Employment, Stock Option. <br><b>AstraZeneca<\/b> Stock. <br><b>Lilly<\/b> Stock. <br><b>J. Boni, <\/b> <br><b>ADC Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>K. Havenith, <\/b> <br><b>ADC Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>Y. LeBruchec, <\/b> <br><b>ADC Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>S. Pantano, <\/b> <br><b>ADC Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>Merck & Co.<\/b> Stock. <br><b>Organon & Co.<\/b> Stock. <br><b>Novartis<\/b> Stock, Patent, Other, Spouse is employee of Novartis and owns Novartis stock. <br><b>Alcon<\/b> Stock, Other, Spouse owns Alcon stock. <br><b>Sandoz<\/b> Stock, Other, Spouse owns Sandoz stock. <br><b>J. Blay, <\/b> <br><b>Bayer<\/b> Other, Research support and honoraria. <br><b>Pharmamar<\/b> Other, Research support and honoraria.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11523","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT059","PresenterBiography":null,"PresenterDisplayName":"McKayla Tassy","PresenterKey":"8a01a907-6645-44c4-a029-11e01c645433","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT059. Phase 1b trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomas","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1b trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomas","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"CD47,Bone marrow,Immune checkpoint,Myelodysplastic Syndrome,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>G. Garcia-Manero<\/b><sup>1<\/sup>, B. L. Scott<sup>2<\/sup>, A. Kishtagari<sup>3<\/sup>, S. R. Sanikommu<sup>4<\/sup>, A. Al-Kali<sup>5<\/sup>, J.-H. Lee<sup>6<\/sup>, J. M. Bergua Burgues<sup>7<\/sup>, M. Diez-Campelo<sup>8<\/sup>, H. P. Erba<sup>9<\/sup>, C. Garcia-Hernandez<sup>10<\/sup>, G. Sanz Santillana<sup>11<\/sup>, C. O'Connell<sup>12<\/sup>, J.-H. Jang<sup>13<\/sup>, D.-Y. Shin<sup>14<\/sup>, H. Sayar<sup>15<\/sup>, M. Rao<sup>16<\/sup>, R. S. Schwartz<sup>16<\/sup>, G. An<sup>16<\/sup>, F. Jin<sup>16<\/sup>, A. J. Forgie<sup>16<\/sup>, A. C. Tsiatis<sup>16<\/sup>, J. K. Altman<sup>17<\/sup>; <br\/><sup>1<\/sup>Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, <sup>3<\/sup>Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, <sup>4<\/sup>Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health,, Charlotte, NC, <sup>5<\/sup>Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, <sup>6<\/sup>Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, <sup>7<\/sup>Servicio de Hematologia y Hemoterapia, Hospital San Pedro de Alcántara, Caceres, Spain, <sup>8<\/sup>Hospital Universitario de Salamanca, Salamanca, Spain, <sup>9<\/sup>Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC, <sup>10<\/sup>Department of Hematology, Hospital General Universitario de Alicante, Alicante, Spain, <sup>11<\/sup>Hospital Universitario y Politécnico La Fe, Valencia, Spain, <sup>12<\/sup>Department of Medicine, University of Southern California - Keck School of Medicine, Los Angeles, CA, <sup>13<\/sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, <sup>14<\/sup>Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>15<\/sup>Indiana University Cancer Center, Indianapolis, IN, <sup>16<\/sup>ALX Oncology Inc., South San Francisco, CA, <sup>17<\/sup>Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL","CSlideId":"","ControlKey":"c4e48945-6ce7-456b-ab50-93efade30186","ControlNumber":"10333","DisclosureBlock":"<b>&nbsp;G. Garcia-Manero, <\/b> <br><b>Chugai Pharma<\/b> Other, Honoraria. <br><b>AstraZeneca<\/b> Other, Honoraria. <br><b>GSB Pharma<\/b> Other, Honoraria. <br><b>Novartis<\/b> Other, Consulting\/advisory role. <br><b>ExCellThera<\/b> Other, Consulting\/advisory role. <br><b>Bristol-Myers Squibb\/Celgene<\/b> Other, Speakers' Bureau. <br><b>Celgene<\/b> Travel. <br><b>BeiGene<\/b> Travel.<br><b>B. L. Scott, <\/b> None..<br><b>A. Kishtagari, <\/b> None..<br><b>S. R. Sanikommu, <\/b> None.&nbsp;<br><b>A. Al-Kali, <\/b> <br><b>ALX Oncology<\/b> Other, support to institution where research is done. <br><b>Novartis<\/b> Other, support to institution where research is done, support to institution for consultancy. <br><b>Hemavant\/H3Biomedicine<\/b> Other, support to institution where research is done. <br><b>ASTEX<\/b> Other, support to institution where research is done. <br><b>support to institution where research is done<\/b> Other, support to institution where research is done. <br><b>Onconova<\/b> Other, support to institution where research is done. <br><b>Medimmune\/AstraZeneca<\/b> Other, support to institution where research is done. <br><b>Aprea Therapeutics<\/b> Other, support to institution where research is done.<br><b>J. Lee, <\/b> None..<br><b>J. M. Bergua Burgues, <\/b> None..<br><b>M. Diez-Campelo, <\/b> None..<br><b>H. P. Erba, <\/b> None..<br><b>C. Garcia-Hernandez, <\/b> None..<br><b>G. Sanz Santillana, <\/b> None..<br><b>C. O'Connell, <\/b> None..<br><b>J. Jang, <\/b> None..<br><b>D. Shin, <\/b> None..<br><b>H. Sayar, <\/b> None.&nbsp;<br><b>M. Rao, <\/b> <br><b>ALX Oncology Inc.<\/b> Employment, Stock, Stock Option. <br><b>R. S. Schwartz, <\/b> <br><b>ALX Oncology Inc.<\/b> Independent Contractor. <br><b>G. An, <\/b> <br><b>ALX Oncology Inc.<\/b> Employment, Stock. <br><b>F. Jin, <\/b> <br><b>ALX Oncology Inc.<\/b> Independent Contractor. <br><b>A. J. Forgie, <\/b> <br><b>ALX Oncology Inc.<\/b> Employment, Stock, Stock Option. <br><b>A. C. Tsiatis, <\/b> <br><b>ALX Oncology Inc.<\/b> Employment, Stock, Stock Option.<br><b>J. K. Altman, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11524","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT060","PresenterBiography":null,"PresenterDisplayName":"Guillermo Garcia-Manero, M.D.","PresenterKey":"33ae3ef7-7fcb-494e-aef5-1d3f38910c33","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT060. Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1 study of azacitidine in combination with evorpacept for higher-risk myelodysplastic syndrome (MDS)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Innate immunity,SUMOylation inhibitor,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D. Stroopinsky<\/b><sup>1<\/sup>, S. Mandzuik<sup>2<\/sup>, D. Anderson<sup>3<\/sup>, J.-Á. Hernández-Rivas<sup>4<\/sup>, H. Assad<sup>5<\/sup>, A. Berger<sup>1<\/sup>, A. Chudnovsky<sup>1<\/sup>, Q. Dong<sup>1<\/sup>, A. Dowlati<sup>6<\/sup>, D. Juric<sup>7<\/sup>, R. Kurzrock<sup>8<\/sup>, I. Lugowska<sup>9<\/sup>, K. Richter<sup>1<\/sup>, J. Rodón<sup>10<\/sup>, D. Schröder<sup>11<\/sup>, S. Kasar<sup>1<\/sup>, A. Olzanski<sup>12<\/sup>; <br\/><sup>1<\/sup>Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, <sup>2<\/sup>Medical University of Lublin, Lublin, Poland, <sup>3<\/sup>HealthPartners Institute, Minneapolis, MN, <sup>4<\/sup>Hematology department, Infanta Leonor University Hospital, Complutense University, Madrid, Spain, <sup>5<\/sup>Karmanos Cancer Institute, Wayne State University, Detroit, MI, <sup>6<\/sup>University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, <sup>7<\/sup>Massachusetts General Hospital Cancer Center, Boston, MA, <sup>8<\/sup>WIN Consortium for Precision Medicine, Chevilly-Larue, France\/Medical College of Wisconsin, Milwaukee, WI, <sup>9<\/sup>Maria Sk&#322;odowska-Curie National Research Institute of Oncology, Warsaw, Poland, <sup>10<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>11<\/sup>Grand Hôpital de Charleroi, Charleroi, Belgium, <sup>12<\/sup>Fox Chase Cancer Center, Philadelphia, PA","CSlideId":"","ControlKey":"2fa60259-0e33-4a61-8eb2-dc37e6e07cb5","ControlNumber":"9506","DisclosureBlock":"<b>&nbsp;D. Stroopinsky, <\/b> <br><b>Takeda<\/b> Employment, Stock, Stock Option.<br><b>S. Mandzuik, <\/b> None..<br><b>D. Anderson, <\/b> None..<br><b>J. Hernández-Rivas, <\/b> None.&nbsp;<br><b>H. Assad, <\/b> <br><b>Gilead<\/b> Other, Speaker. <br><b>Stemline<\/b> Other, Speaker. <br><b>A. Berger, <\/b> <br><b>Takeda Development Center Americas, Inc.<\/b> Employment. <br><b>Takeda Pharmaceuticals Inc<\/b> Stock. <br><b>A. Chudnovsky, <\/b> <br><b>Takeda<\/b> Employment. <br><b>Q. Dong, <\/b> <br><b>Takeda<\/b> Employment. <br><b>A. Dowlati, <\/b> <br><b>Ipsen<\/b> Other, Advisory board. <br><b>BMS<\/b> Other, Advisory board. <br><b>Jazz<\/b> Other, Advisory board. <br><b>Puma<\/b> Other, Advisory board. <br><b>Prelude<\/b> Other, Advisory board. <br><b>AstraZeneca<\/b> Other, Advisory board. <br><b>Amgen<\/b> Other, Advisory board. <br><b>D. Juric, <\/b> <br><b>Novartis<\/b> Grant\/Contract, Other, Consulting fees. <br><b>Genentech<\/b> Grant\/Contract, Other, Consulting fees. <br><b>Syros<\/b> Grant\/Contract, Other, Consulting fees. <br><b>Eisai<\/b> Grant\/Contract, Other, Consulting fees. <br><b>Vibliome<\/b> Other, Consulting fees. <br><b>PIC Therapeutics<\/b> Other, Consulting fees. <br><b>Mapkure<\/b> Other, Consulting fees. <br><b>Relay Therapeutics<\/b> Other, Consulting fees. <br><b>Eli Lilly<\/b> Grant\/Contract, Other, Consulting fees. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Amgen<\/b> Grant\/Contract. <br><b>InventisBio<\/b> Grant\/Contract. <br><b>Arvinas<\/b> Grant\/Contract. <br><b>Takeda<\/b> Grant\/Contract. <br><b>Blueprint<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Ribon Therapeutics<\/b> Grant\/Contract. <br><b>Infinity<\/b> Grant\/Contract. <br><b>R. Kurzrock, <\/b> <br><b>Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Sequenom, Takeda, and TopAlliance and from the N<\/b> Grant\/Contract. <br><b>Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Datar Cancer Genetics, Daiichi, EISAI, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed<\/b> Other, Consultant and\/or speaker fees and\/or advisory board\/consultant. <br><b>Pfizer<\/b> Grant\/Contract, Other, Consultant and\/or speaker fees and\/or advisory board\/consultant. <br><b>CureMatch Inc<\/b> Other, Equity interest; serves on the board and is a co-founder. <br><b>IDbyDNA<\/b> Other, Equity interest. <br><b>CureMetrix<\/b> Other, Serves on the board. <br><b>I. Lugowska, <\/b> <br><b>Amgen<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract. <br><b>BMS<\/b> Grant\/Contract. <br><b>Loxo<\/b> Grant\/Contract. <br><b>BI<\/b> Grant\/Contract. <br><b>MSD<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Ascendis<\/b> Grant\/Contract. <br><b>Tesaro<\/b> Grant\/Contract. <br><b>Ryvu<\/b> Grant\/Contract. <br><b>K. Richter, <\/b> <br><b>Takeda<\/b> Employment, Stock, Stock Option. <br><b>J. Rodón, <\/b> <br><b>Ellipses Pharma, Molecular Partners, IONCTURA, Sardona, Mekanistic, Amgen, Merus, MonteRosa, Aadi, Bridgebio<\/b> Other, Advisory board. <br><b>Blueprint Medicines, Merck Sharp & Dohme, Hummingbird, AstraZenneca, Yingli, Vall d'Hebron Institute of Oncology\/Cancer Core Europe<\/b> Other, Research funding. <br><b>Cancer Core Europe, Symphogen, BioAlta, Pfizer, Kelun-Biotech, GlaxoSmithKline, Taiho, Roche Pharmaceuticals, Hummingbird, Yingli, Bicycle Therapeutics, Merus, AadiBioscience, ForeBio, Loxo Oncology<\/b> Other, Clinical research. <br><b>Hutchinson MediPharma, Ideaya, Amgen, Tango Therapeutics, Mirati, Linnaeus Therapeutics, MonteRosa, Kinnate, Debio, BioTheryX, Storm Therapeutics, Beigene, MapKure, Relay, Novartis, FusionPharma<\/b> Other, Clinical research. <br><b>C4 Therapeutics, Scorpion Therapeutics, Incyte, Fog Pharmaceuticals, Tyra, Nuvectis Pharma, Bridgebio Pharma, 3H Pharmaceuticals<\/b> Other, Clinical research. <br><b>Vall d'Hebron Institute of Oncology\/Ministero De Empleo Y Seguridad Social, Chinese University of Hong Kong, Boxer Capital, LLC, Tang Advisors, LLC, Guidepoint<\/b> Other.<br><b>D. Schröder, <\/b> None.&nbsp;<br><b>S. Kasar, <\/b> <br><b>Takeda Pharmaceuticals<\/b> Employment. <br><b>A. Olzanski, <\/b> <br><b>Merck, BMS, Pfizer, Novartis, Eisai, Nektar, InstilBio, Oncosec, Replimune<\/b> Other, Advisory boards and DSMBs.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11525","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT061","PresenterBiography":null,"PresenterDisplayName":"Dina Stroopinsky, PhD","PresenterKey":"f62dfbd0-a6d7-4bf4-b76a-8824f7e11ac8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT061. Pharmacodynamic analysis from a phase 1\/2 study of subasumstat (TAK-981) as single agent in patients (pts) with advanced\/refractory metastatic solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Pharmacodynamic analysis from a phase 1\/2 study of subasumstat (TAK-981) as single agent in patients (pts) with advanced\/refractory metastatic solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Axl,Mer,Solid tumors,Tyrosine kinase inhibitor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Y. Katsuya<\/b><sup>1<\/sup>, K. Yonemori<sup>1<\/sup>, T. Shimizu<sup>1<\/sup>, T. Koyama<sup>1<\/sup>, S. Kitano<sup>1<\/sup>, K. Sudo<sup>1<\/sup>, S. Kondo<sup>1<\/sup>, J. Sato<sup>1<\/sup>, H. Hozumi<sup>2<\/sup>, N. Yamamoto<sup>1<\/sup>; <br\/><sup>1<\/sup>Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, <sup>2<\/sup>ONO Pharmaceutical Co., Ltd., Osaka, Japan","CSlideId":"","ControlKey":"58b89b3f-e36a-42eb-864f-1c353f92017d","ControlNumber":"9589","DisclosureBlock":"<b>&nbsp;Y. Katsuya, <\/b> <br><b>Ono Pharmaceutical Co., Ltd.<\/b> Grant\/Contract. <br><b>K. Yonemori, <\/b> <br><b>MSD; AstraZeneca; Takeda; Sanofi; Eisai.<\/b> Grant\/Contract, Other, Honorarium for lecture and Advisory Board. <br><b>Daiichi-Sankyo; Pfizer; Chugai; Ono; Eli Lilly; Boehringer Ingelheim.<\/b> Grant\/Contract, Other, Honorarium for lecture. <br><b>Novartis; Genmab.<\/b> Grant\/Contract, Other, Advisory Board. <br><b>Merck Biopharma; Taiho; Seattle genetics; Kyowa Hakko Kirin; Nihon Kayaku; Haihe.<\/b> Grant\/Contract. <br><b>Fuji Film Pharma; PDR pharma; Bayer; Jansen.<\/b> Other, Honorarium for lecture. <br><b>Gilead; OncXerna; Henlius.<\/b> Other, Advisory Board. <br><b>T. Shimizu, <\/b> <br><b>Ono; Eli Lilly; LOXO Oncology; Daiichi-Sankyo; Novartis; Eisai; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; Incyte; Astellas Pharma; Pfizer; Symbio Pharmaceuticals.<\/b> Grant\/Contract. <br><b>AbbVie; Chordia Therapeutics.<\/b> Grant\/Contract, Other, Advisory role. <br><b>Chugai; MSD; Taiho; IQVIA.<\/b> Other, Speaker fee. <br><b>T. Koyama, <\/b> <br><b>Ono; Daiichi-Sankyo; Eli Lilly; Takeda; Janssen; Zymeworks.<\/b> Grant\/Contract. <br><b>Chugai; AstraZeneca; Novartis.<\/b> Grant\/Contract, Other, honoraria. <br><b>Sysmex.<\/b> Other, honoraria. <br><b>S. Kitano, <\/b> <br><b>Ono; Astra Zeneca; Pfizer; Boehringer Ingelheim; MSD; Eisai; GSK; Daiichi-Sankyo; Chugai; Takeda.<\/b> Grant\/Contract, Other, Lecture fee. <br><b>Taiho; Novartis; Bristol-Myers Squibb; Merck KGaA.<\/b> Other, Lecture fee. <br><b>Sumitomo Pharma; ImmuniT Research Inc.<\/b> Other, Scientific advisor. <br><b>Astellas; Takara Bio Inc; Incyte; Abbvie; Eli Lilly \/LOXO Oncology.<\/b> Grant\/Contract. <br><b>Rakuten Medical; United Immunity.<\/b> Grant\/Contract, Other, Scientific Advisor. <br><b>K. Sudo, <\/b> <br><b>Ono; NanoCarrier; Daiichi Sankyo; AstraZeneca; Pfizer; Amgen; PRA Health Sciences; Merck; Takeda.<\/b> Grant\/Contract. <br><b>S. Kondo, <\/b> <br><b>Ono; Eisai; Abbvie; Astellas; AstraZeneca.<\/b> Grant\/Contract. <br><b>Sanofi<\/b> Other, Advisor. <br><b>InventisBio<\/b> Travel. <br><b>J. Sato, <\/b> <br><b>Ono Pharmaceutical Co., Ltd.<\/b> Grant\/Contract. <br><b>Eisai; Chugai Pharmaceutzical Co; Fuji Film.<\/b> Other, honoraria as speakers. <br><b>H. Hozumi, <\/b> <br><b>ONO Pharmaceutical Co., Ltd.<\/b> Employment. <br><b>N. Yamamoto, <\/b> <br><b>Ono; Daiichi-Sankyo.<\/b> Grant\/Contract, Other, Honoraria as Speakers (personal). <br><b>Chugai; Eisai.<\/b> Grant\/Contract, Other, Advisory role (personal) and Honoraria as Speakers (personal). <br><b>Takeda; Boehringer Ingelheim; Cmic; MERCK<\/b> Grant\/Contract, Other, Advisory role (personal). <br><b>Astellas; Taiho; BMS; Pfizer; Novartis; Eli Lilly; AbbVie; Bayer; Kyowa Kirin; Janssen Pharma; MSD; GSK; Sumitomo Pharma; Chiome Bioscience; Otsuka; Carna Biosciences; Genmab; Shionogi; TORAY; KAKEN.<\/b> Grant\/Contract. <br><b>AstraZeneca; InventisBio; Rakuten Medical.<\/b> Grant\/Contract. <br><b>Healios.<\/b> Other, Advisory role (personal).","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11526","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT062","PresenterBiography":null,"PresenterDisplayName":"Yuki Katsuya, MD, PhD","PresenterKey":"36840c3f-4fe8-4fee-953f-89a0e02ecb9b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT062. A phase 1 study of tamnorzatinib (ONO-7475), an Axl\/Mer dual inhibitor, alone and in combination with nivolumab in patients with advanced or metastatic solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1 study of tamnorzatinib (ONO-7475), an Axl\/Mer dual inhibitor, alone and in combination with nivolumab in patients with advanced or metastatic solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"DNA damage response,ATR,ATM,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>L. L. Siu<\/b><sup>1<\/sup>, E. Cabanas<sup>2<\/sup>, V. Boni<sup>3<\/sup>, A. W. Tolcher<sup>4<\/sup>, E. Sanz Garcia<sup>1<\/sup>, J. Fuentes-Antrás<sup>3<\/sup>, O. Saavedra<sup>2<\/sup>, D. S. Vagge<sup>5<\/sup>, G. Locatelli<sup>6<\/sup>, B. Günhan<sup>6<\/sup>, G. Pennock<sup>7<\/sup>, J. Mukker<sup>7<\/sup>, I. Gounaris<sup>8<\/sup>, T. A. Yap<sup>9<\/sup>; <br\/><sup>1<\/sup>Princess Margaret Cancer Centre, Toronto, ON, Canada, <sup>2<\/sup>New Experimental Therapeutics (NEXT) Oncology, Hospital Universitario Quirónsalud, Barcelona, Spain, <sup>3<\/sup>New Experimental Therapeutics (NEXT) Oncology, Hospital Universitario Quirónsalud, Madrid, Spain, <sup>4<\/sup>New Experimental Therapeutics (NEXT) Oncology, San Antonio, TX, <sup>5<\/sup>Merck Specialities Pvt. Ltd., (an affiliate of Merck KGaA, Darmstadt, Germany), Bangalore, India, <sup>6<\/sup>the healthcare business of Merck KGaA, Darmstadt, Germany, <sup>7<\/sup>EMD Serono, Billerica, MA, <sup>8<\/sup>Merck Serono Ltd., (an affiliate of Merck KGaA, Darmstadt, Germany), Feltham, United Kingdom, <sup>9<\/sup>University of Texas MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"4226f1c8-55a2-4761-b421-263ba1141cdd","ControlNumber":"10352","DisclosureBlock":"<b>&nbsp;L. L. Siu, <\/b> <br><b>Princess Margaret Cancer Centre, Toronto, Canada<\/b> Employment. <br><b>Agios<\/b> Other, Stock (spouse). <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, GlaxoSmithKline, Roche\/Genentech, AstraZeneca, Merck & Co., Kenilworth, NJ<\/b> Grant\/Contract. <br><b>Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Mirati, BioNTech, 23Me, Gilead, Seattle Genetics, Loxo, Takeda, Bicara<\/b> Grant\/Contract. <br><b>Treadwell Therapeutics<\/b> Other, Other Intellectual Property (co-founder, spouse). <br><b>Merck & Co., Kenilworth NJ, Pfizer, AstraZeneca, Roche, GlaxoSmithKline, Voronoi, Arvinas, Navire, Relay, Daiichi Sankyo, Amgen, Marengo, Medicenna, Tubulis, LTZ Therapeutics, Pangea<\/b> Other, Consultant\/Advisory Board. <br><b>E. Cabanas, <\/b> <br><b>NEXT Oncology - Hospital Quirónsalud, Barcelona, Spain<\/b> Employment. <br><b>1TRIALSP<\/b> Stock. <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Thermo Fisher, AstraZeneca, Taiho, BeiGene, Janssen<\/b> Grant\/Contract. <br><b>Roche, Ellipses Pharma, Boehringer Ingelheim, Janssen Global Services, Seattle Genetics, Thermo Fisher, MabDiscovery, Anaveon, F-Star Therapeutics, Hengrui, Sanofi, Incyte, Medscape<\/b> Other, Consulting fees. <br><b>Merck & Co., Kenilworth NJ, Roche, Thermo Fisher, Novartis, SeaGen<\/b> Other, Speaker honoraria. <br><b>V. Boni, <\/b> <br><b>NEXT Oncology Madrid, Universitary Hospital Quiron Salud Madrid<\/b> Employment. <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany<\/b> Grant\/Contract. <br><b>A. W. Tolcher, <\/b> <br><b>ABBVIE, Inc, Aclaris Therapeutics, Affinia Therapeutics, Inc, AGENUS, Inc., ASANA BIOSCIENCES, ASCENTAGE, Astex Pharmaceuticals, Axlmmune, Bayer, Blu Print Oncology, Daiichi Sankyo, Inc.<\/b> Other, Consulting. <br><b>Exelixis, Inc., GILDE HEALTHCARE PARTNERS, HBM PARTNERS, IDEA Pharma, Ikena Oncology, Immuneering, Immunomet Therapeutics, Inc., Impact Therapeutics US, Inc.<\/b> Other, Consulting. <br><b>Karma Oncology B.V., Kirilys Therapeutics, Inc., Lengo Therapeutics, Inc., Link Immunotherapeutics, Medicxi, Mekanistic Therapeutics, Menarini Ricerche, Mersana, NANOBIOTIX<\/b> Other, Consulting. <br><b>Nerviano Medical Sciences S.r.I. (NMS), Novo Nordisk Inc., Nurix Therapeutics, Ocellaris Pharma, Inc. & Eli Lilly, Partner Therapeutics, Pfizer Inc., PIERRE FABRE, PYRAMID BIOSCIENCES<\/b> Other, Consulting. <br><b>Qualigen Therapeutics, Roche, RYVU THERAPEUTICS, Seattle Genetics, Singzyme Pte Ltd, SK Life Science, SOTIO Biotechnology Co., Senti Biosciences, Sun Pharma Advanced Research Company (SPARC)<\/b> Other, Consulting. <br><b>TheraTechnologies, Transcenta Therapeutics Inc., Transgene, Trillium Therapeutics Inc., Venus Oncology, Verastem Oncology<\/b> Other, Consulting. <br><b>ADAGENE, Inc., BIOINVENT, Boeringer Ingelheim International GmbH, Bright Peak Therapeutics, Cullinan Oncology, Elucida Oncology, EMD Serono<\/b> Other, Ad board. <br><b>IMMUNOME, JAZZ, MIRATI, NBE THERAPEUTICS, Nested Therapeutics, Inc., Pheon Therapeutics, PYXIS Oncology, Roche, Spirea Limited Inc., Vincerx, VRISE Therapeutics, Inc., Zentalis, Pharmaceuticals<\/b> Other, Ad board. <br><b>ZielBio, Inc.<\/b> Other, Ad board. <br><b>NEXT Oncology, San Antonio, TX, USA<\/b> Other, Leadership role. <br><b>E. Sanz Garcia, <\/b> <br><b>Princess Margaret Cancer Centre, Toronto, Canada<\/b> Employment. <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany<\/b> Grant\/Contract. <br><b>J. Fuentes-Antrás, <\/b> <br><b>NEXT Oncology, Hospital Universitario Quirónsalud, Madrid, Spain<\/b> Employment. <br><b>Lilly, the healthcare business of Merck KGaA, Darmstadt, Germany, EUSA Pharma<\/b> Other, Research grant\/award. <br><b>Exelixis<\/b> Travel. <br><b>Sysmex<\/b> Other, Speaker's bureau.<br><b>O. Saavedra, <\/b> None.&nbsp;<br><b>D. S. Vagge, <\/b> <br><b>Merck Specialities Pvt. Ltd., Bangalore, India, an affiliate of Merck KGaA, Darmstadt, Germany<\/b> Employment. <br><b>G. Locatelli, <\/b> <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany<\/b> Employment. <br><b>B. Günhan, <\/b> <br><b>the healthcare business of Merck KGaA, Darmstadt, Germany<\/b> Employment. <br><b>G. Pennock, <\/b> <br><b>EMD Serono, Billerica, MA USA<\/b> Employment. <br><b>J. Mukker, <\/b> <br><b>EMD Serono, Billerica, MA USA<\/b> Employment. <br><b>I. Gounaris, <\/b> <br><b>Merck Serono Ltd., Feltham, UK, an affiliate of Merck KGaA, Darmstadt, Germany<\/b> Employment. <br><b>Novartis, Alcon, Sandoz<\/b> Stock. <br><b>T. A. Yap, <\/b> <br><b>University of Texas MD Anderson Cancer Center<\/b> Employment, Other, Employee of University of Texas MD Anderson Cancer Center, where he is Vice President, Head of Clinical Development in the Therapeutics Discovery Division, which has a commercial interest in DDR and other inhibitors (IACS30380\/ART0380 was licensed to Artios). <br><b>AbbVie, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, BioCity Pharma, Blueprint, Boxer<\/b> Other, Consultant. <br><b>Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics, Diffusion, Duke Street Bio<\/b> Other, Consultant. <br><b>858 Therapeutics, EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, F-Star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Ideaya Biosciences, Idience<\/b> Other, Consultant. <br><b>Ignyta, I-Mab, ImmuneSensor, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck & Co., Kenilworth, NJ, Merit, Monte Rosa Therapeutics, Natera<\/b> Other, Consultant. <br><b>Nested Therapeutics, Nexys, Nimbus, Novocure, Odyssey, OHSU, OncoSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, PER, Pfizer, Piper-Sandler, Pliant Therapeutics, Prolynx<\/b> Other, Consultant. <br><b>Radiopharma Theranostics, Repare, resTORbio, Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2<\/b> Other, Consultant. <br><b>Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals, Tolremo, Tome, Thryv Therapeutics, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Voronoi Inc, Xinthera, Zai Labs<\/b> Other, Consultant. <br><b>ZielBio<\/b> Other, Consultant. <br><b>Acrivon, Artios, AstraZeneca, Bayer, Beigene, BioNTech, Blueprint, BMS, Boundless Bio, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star<\/b> Other, Grant\/Research support. <br><b>GlaxoSmithKline, Genentech, Haihe, Ideaya ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck & Co., Kenilworth NJ, Mirati, Novartis, Pfizer, Ribon Therapeutics<\/b> Other, Grant\/Research support. <br><b>Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tango, Tesaro, Vivace and Zenith<\/b> Other, Grant\/Research support. <br><b>Seagen<\/b> Stock.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11527","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT063","PresenterBiography":null,"PresenterDisplayName":"Janeen Nuttall","PresenterKey":"fa7eb4e6-45b7-4b77-832c-92fbc5862757","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT063. Phase Ib trial of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase Ib trial of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib (M4076) in patients (pts) with advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Pharmacokinetics,WEE1,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Bellon<\/b><sup>1<\/sup>, O. Saavedra<sup>2<\/sup>, I. M. E. Desar<sup>3<\/sup>, M. Jalving<sup>4<\/sup>, J. A. Gietema<sup>4<\/sup>, C. van Herpen<sup>3<\/sup>, S. van Ravensteijn<sup>3<\/sup>, E. Rodrigo Imedio<sup>1<\/sup>, S. van Haren<sup>1<\/sup>, M. Wirth<sup>1<\/sup>, S. Micallef<sup>1<\/sup>, V. Dozio<sup>1<\/sup>, R. Frederiksen Franzen<sup>1<\/sup>, M.-C. Roubaudi-Fraschini<sup>1<\/sup>, V. Nicolas-Metral<sup>1<\/sup>, H. Gelderblom<sup>5<\/sup>; <br\/><sup>1<\/sup>Debiopharm International S.A., Lausanne, Switzerland, <sup>2<\/sup>Vall d'Hebron University Hospital, Barcelona, Spain, <sup>3<\/sup>Radboud University Medical Center, Nijmegen, Netherlands, <sup>4<\/sup>University Medical Center Groningen (UMCG), Groningen, Netherlands, <sup>5<\/sup>Leiden University Medical Center, Leiden, Netherlands","CSlideId":"","ControlKey":"82d6d844-a35b-4d29-8d1c-ec2ba60f1821","ControlNumber":"9582","DisclosureBlock":"<b>&nbsp;A. Bellon, <\/b> <br><b>Debiopharm International<\/b> Employment. <br><b>O. Saavedra, <\/b> <br><b>Debiopharm International<\/b> Other, Principal investigator in the clinical trial. <br><b>I. M. E. Desar, <\/b> <br><b>Debiopharm International<\/b> Other, Principal investigator in the clinical trial. <br><b>M. Jalving, <\/b> <br><b>Debiopharm International<\/b> Other, Principal investigator in the clinical trial. <br><b>J. A. Gietema, <\/b> <br><b>Debiopharm International<\/b> Other, co-investigator in the clinical trial. <br><b>C. van Herpen, <\/b> <br><b>Debiopharm International<\/b> Other, co-investigator in the clinical trial. <br><b>S. van Ravensteijn, <\/b> <br><b>Debiopharm International<\/b> Other, co-investigator in the clinical trial. <br><b>E. Rodrigo Imedio, <\/b> <br><b>Debiopharm International<\/b> Employment. <br><b>BioNTech<\/b> Stock. <br><b>S. van Haren, <\/b> <br><b>Debiopharm International<\/b> Independent Contractor. <br><b>M. Wirth, <\/b> <br><b>Debiopharm International<\/b> Employment. <br><b>S. Micallef, <\/b> <br><b>Debiopharm International<\/b> Employment. <br><b>V. Dozio, <\/b> <br><b>Debiopharm International<\/b> Employment. <br><b>R. Frederiksen Franzen, <\/b> <br><b>Debiopharm International<\/b> Employment. <br><b>M. Roubaudi-Fraschini, <\/b> <br><b>Debiopharm International<\/b> Employment. <br><b>V. Nicolas-Metral, <\/b> <br><b>Debiopharm International<\/b> Employment. <br><b>H. Gelderblom, <\/b> <br><b>Debiopharm International<\/b> Other, Coordinating Principal Investigator.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11528","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT064","PresenterBiography":null,"PresenterDisplayName":"Anne Bellon, PhD;Pharm D","PresenterKey":"1b9018f5-f1be-4e07-bc19-f93d3bcbe09e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT064. Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a phase 1 dose escalation study","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a phase 1 dose escalation study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Immunotherapy,Innate immunity,Interferons,Solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>G. Saggu<\/b>, J. L. Markman, M. Lee, F. Dunbar, A. Joshi, S. Wang, S. Collins; <br\/>Takeda Development Center Americas, Inc. (TDCA), Lexington, MA","CSlideId":"","ControlKey":"967dcf67-a12c-49a9-956f-d47e7d4e53be","ControlNumber":"9698","DisclosureBlock":"<b>&nbsp;G. Saggu, <\/b> <br><b>Takeda<\/b> Employment. <br><b>J. L. Markman, <\/b> <br><b>Takeda<\/b> Employment. <br><b>M. Lee, <\/b> <br><b>Takeda<\/b> Employment, Stock. <br><b>F. Dunbar, <\/b> <br><b>Takeda<\/b> Employment. <br><b>A. Joshi, <\/b> <br><b>Takeda<\/b> Employment, Stock. <br><b>S. Wang, <\/b> <br><b>Takeda<\/b> Employment, Stock. <br><b>S. Collins, <\/b> <br><b>Takeda<\/b> Employment, Stock.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11529","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT065","PresenterBiography":null,"PresenterDisplayName":"Gurpanna Saggu, PhD","PresenterKey":"d487011f-17ce-4907-899b-f1fa7318a31b","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT065. Modakafusp alfa shows intratumoral immune pharmacodynamics (PD) in a subset of patients (pts) in a phase 1b study in advanced\/metastatic solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Modakafusp alfa shows intratumoral immune pharmacodynamics (PD) in a subset of patients (pts) in a phase 1b study in advanced\/metastatic solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Solid tumors,TP53,MDM2,Pharmacokinetics,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>E. E. Dumbrava<\/b><sup>1<\/sup>, F. M. Iwamoto<sup>2<\/sup>, M. Agulnik<sup>3<\/sup>, M. Milhem<sup>4<\/sup>, A. W. Tolcher<sup>5<\/sup>, R. Chugh<sup>6<\/sup>, M. J. Demeure<sup>7<\/sup>, A. Mita<sup>8<\/sup>, K. Demel<sup>9<\/sup>, M. Diamond<sup>10<\/sup>, B. Mirakhur<sup>11<\/sup>, L. Wilson<sup>11<\/sup>, A. Oganesian<sup>11<\/sup>, D. Chan<sup>11<\/sup>, H. N. Keer<sup>11<\/sup>, J. Taylor<sup>11<\/sup>, M. J. Sims<sup>12<\/sup>, A. Biondo<sup>12<\/sup>, S. Jueliger<sup>12<\/sup>, A. Spira<sup>13<\/sup>; <br\/><sup>1<\/sup>The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Columbia University Iving Medical Center, New York, NY, <sup>3<\/sup>City of Hope Comprehensive Cancer Center, Duarte, CA, <sup>4<\/sup>University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA, <sup>5<\/sup>NEXT Oncology, San Antonio, TX, <sup>6<\/sup>University of Michigan Rogel Cancer Center, Ann Arbor, MI, <sup>7<\/sup>Hoag Memorial Hospital Presbyterian, Newport Beach, CA, <sup>8<\/sup>Cedars-Sinai Medical Center, Los Angeles, CA, <sup>9<\/sup>Regions Hospital\/HealthPartners Cancer Research Center, Saint Paul, MN, <sup>10<\/sup>University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, <sup>11<\/sup>Astex Pharmaceuticals, Inc., Pleasanton, CA, <sup>12<\/sup>Astex Pharmaceuticals, Cambridge, United Kingdom, <sup>13<\/sup>Virginia Cancer Specialists Fairfax, Fairfax, VA","CSlideId":"","ControlKey":"174d9904-b8f1-4c82-9dcf-b63b2a78e92e","ControlNumber":"9788","DisclosureBlock":"<b>&nbsp;E. E. Dumbrava, <\/b> <br><b>Bayer HealthCare Pharmaceuticals Inc, Immunocore LTD, Amgen, Aileron Therapeutics, Compugen Ltd, TRACON Pharmaceuticals Inc, Unum Therapeutics, Gilead Immunomedics, BOLT Therapeutics<\/b> Grant\/Contract, Other, Research funding. <br><b>Aprea Therapeutics, Bellicum Pharmaceuticals, PMV Pharma, Triumvira Immunologics, Seagen Inc, Mereo BioPharma 5 Inc, Sanofi, Rain Oncology, Astex Therapeutics, Sotio, Poseida, Mersana Therapeutics<\/b> Grant\/Contract, Other, research funding. <br><b>Genentech, Boehringer Ingelheim, Dragonfly Therapeutics, A2A Pharmaceuticals<\/b> Grant\/Contract, Other, research funding. <br><b>BOLT Therapeutics, Mersana Therapeutics, Orum Therapeutics, Summit Therapeutics, Fate Therapeutics, PMV Pharma<\/b> Other, Advisory board. <br><b>PMV Pharma<\/b> Other, speaker program. <br><b>ASCO, LFSA Association, Rain Oncology, Banner MD Anderson Cancer Center, Triumvira Immunologics<\/b> Travel. <br><b>F. M. Iwamoto, <\/b> <br><b>Anheart, Novocure, Praesidia      Guidepoint Global, Mimivax<\/b> Other, Consultancy. <br><b>Anheart, ABM, Sapience Therapeutics, Novocure, Pfizer<\/b> Other, Research funding. <br><b>M. Agulnik, <\/b> <br><b>Regeneron, AADi, Coherus Biosciences<\/b> Other, consulting or advisory role. <br><b>Bayer, Deciphera<\/b> Other, speakers bureau. <br><b>Exelixis<\/b> Other, research funding.<br><b>M. Milhem, <\/b> None.&nbsp;<br><b>A. W. Tolcher, <\/b> <br><b>Qualigen Therapeutics ABBVIE, Inc Roche, Aclaris Therapeutics, RYVU Therapeutics, Affinia Therapeutics, Inc Seattle Genetics, AGENUS Inc. Singzyme Pte Ltd, ASANA Biosiences, SK Life Science<\/b> Other, consulting. <br><b>ASCENTAGE SOTIO Biotechnology Co., Astex Pharmaceuticals, Senti Biosciences, Axlmmune, Sun Pharma Advanced Research Company (SPARC), Bayer, Thera Technologies, Blu Print Oncology, Transcenta Therapeu<\/b> Other, consulting. <br><b>Therapeutics Inc., Daiichi Sankyo, Inc., Transgene, Exelixis, Inc. Trillium Therapeutics Inc., Glide Healthcare Partners, Venus Oncology, HBM Partners, Verastem Oncology, IDEA Pharma, Ikena Oncology<\/b> Other, consulting. <br><b>Immuneering, Immunomet Therapeutics, Inc., Impact Therapeutics US, Inc., Karma Oncology, B.V., Kirilys Therapeutics, Inc., Lengo Therapeutics, Inc., Medicxi, Mekanistic Therapeutics, Menarini Ricerch<\/b> Other, consulting. <br><b>Mersana, NANOBIOTIX, Nerviano Medical Sciences S.r.I.  (NMS), Novo Nordisk Inc., Nurix Therapeutics, Ocellaris Pharma, Inc. & Eli Lilly, Partner Therapeutics, Pfizer Inc., Pierre Fabre, PYRAMID Biosc<\/b> Other, consulting. <br><b>ADAGENE, Inc., BIOINVENT, Boeringer Ingelheim International GmbH, Bright Peak Therapeutics, Cullinan Oncology, Elucida Oncology, EMD SERONO\/ MERCK KGaA<\/b> Other, advisory board member. <br><b>, Link Immunotherapeutics, IMMUNOME, JAZZ, MIRATI, NBE THERAPEUTICS, Nested Therapeutics, Inc., Pheon Therapeutics, PYXIS Oncology, Roche, Spirea Limited Inc., Vincerx, VRISE Therapeutics, Inc.,<\/b> Other, advisory board member. <br><b>Zentalis Pharmaceuticals, ZielBio, Inc.<\/b> Other, advisory board member. <br><b>R. Chugh, <\/b> <br><b>Springworks, Inhibrx, Deciphera, Jazz Pharmaceuticals<\/b> Other, Consulting. <br><b>Springworks, Inhibrx, Deciphera, Jazz Pharmaceuticals, Ayala, Astex Pharmaceuticals, Cogent Biosciences, Advenchen, , Epizyme, Mundipharma, Glaxxo Smith Kline, Cornerstone, Kronos Bio, Pfizer, PTC Th<\/b> Other, Research funding. <br><b>UpToDate, Inc.<\/b> Patent. <br><b>M. J. Demeure, <\/b> <br><b>Lilly, Orphagen, Theralink, Bayer, TD2 OnCusp, Pfizer, Aadi Biosciences, & Boehringer Ingelheim<\/b> Other, consultant.<br><b>A. Mita, <\/b> None..<br><b>K. Demel, <\/b> None..<br><b>M. Diamond, <\/b> None.&nbsp;<br><b>B. Mirakhur, <\/b> <br><b>Astex Pharmaceuticals, Inc.<\/b> Employment. <br><b>L. Wilson, <\/b> <br><b>Astex Pharmaceuticals, Inc.<\/b> Employment. <br><b>A. Oganesian, <\/b> <br><b>Astex Pharmaceuticals, Inc.<\/b> Employment. <br><b>D. Chan, <\/b> <br><b>Astex Pharmaceuticals, Inc.<\/b> Employment. <br><b>H. N. Keer, <\/b> <br><b>Astex Pharmaceuticals, Inc.<\/b> Employment. <br><b>J. Taylor, <\/b> <br><b>Astex Pharmaceuticals, Inc.<\/b> Employment. <br><b>M. J. Sims, <\/b> <br><b>Astex Pharmaceuticals<\/b> Employment. <br><b>A. Biondo, <\/b> <br><b>Astex Pharmaceuticals<\/b> Employment. <br><b>S. Jueliger, <\/b> <br><b>Astex Pharmaceuticals<\/b> Employment. <br><b>A. Spira, <\/b> <br><b>NEXT Oncology Virginia<\/b> Other, Leadership. <br><b>Eli Lilly<\/b> Stock, Other Business Ownership. <br><b>CytomX Therapeutics, AstraZeneca\/MedImmune, Merck, Janssen Oncology, Novartis, Bristol Myers Squibb, Takeda, Amgen, Bayer<\/b> Other, honoraria. <br><b>Incyte, Amgen, Novartis, Mirati Therapeutics, Gritstone Oncology,  Jazz Pharmaceuticals, Takeda, Janssen Research & Development, Gritstone Bio, Mersana, Daiichi Sankyo\/Astra Zeneca, Regeneron, Lily<\/b> Consulting\/advisory role. <br><b>Black Diamond Therapeutics, Sanofi, Array Biopharma, AstraZeneca\/MedImmune, Merck, Bristol Meyers Squibb, Blueprint Medicines<\/b> Other, Consulting\/advisory role. <br><b>LAM Therapeutics, Regeneron, Roche, AstraZeneca, Boehringer Ingelheim, Astellas Pharma, MedImmune, Novartis, Incyte, Abbvie, Ignyta, Takeda, Macrogenics, CytomX Therapeutics, Astex Pharmaceuticals<\/b> Other, research funding. <br><b>Bristol-Myers Squibb, Loxo, Arch Therapeutics, Gritstone, Plexxikon, Amgen, Loxo, Daiichi Sankyo, ADCT, Janssen Oncology, Mirati Therapeutics, ADCT, Rubius, Synthekine<\/b> Other, research funding. <br><b>Mersana, Blueprint Medicines, Alkermes, Revolution Medicines, Medikine, Synthekine, Black Diamond Therapeutics, BluePrint Oncology, Nalo therapeutics, Scorpion Therapeutics, ArriVent, Revolution Med<\/b> Other, research funding.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11530","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT066","PresenterBiography":null,"PresenterDisplayName":"Ecaterina Dumbrava, MD","PresenterKey":"b5a9d78d-5dd5-487f-99fa-e3aa7f8f8a38","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT066. Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Multiple myeloma,Amanitin,Antibody-drug conjugate (ADC),RNA Polymerase II,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"J. Kaufman<sup>1<\/sup>, M. Raab<sup>2<\/sup>, S. Richard<sup>3<\/sup>, S. Grosicki<sup>4<\/sup>, I. Takács<sup>5<\/sup>, <b>A. Strassz<\/b><sup>6<\/sup>, A. Pahl<sup>6<\/sup>, M. Kulke<sup>6<\/sup>, T. Michael<sup>6<\/sup>, A. Last<sup>6<\/sup>, H. Szabóki<sup>6<\/sup>, G. Jentsch<sup>7<\/sup>, O. Schönborn-Kellenberger<sup>8<\/sup>, R. Orlowski<sup>9<\/sup>; <br\/><sup>1<\/sup>Winship Cancer Institute, Emory University, Atlanta, GA, <sup>2<\/sup>Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany, <sup>3<\/sup>Icahn school of Medicine at Mount Sinai, New York, NY, <sup>4<\/sup>Medical University in Silesia, Katowice, Poland, <sup>5<\/sup>Semmelweis University, Department of the Internal Medicine and Oncology, Budapest, Hungary, <sup>6<\/sup>Heidelberg Pharma AG, Ladenburg, Germany, <sup>7<\/sup>BAST, Heidelberg, Germany, <sup>8<\/sup>Cogitars GmbH, Heidelberg, Germany, <sup>9<\/sup>Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"d6b71425-f363-468d-9579-b7d7f50a2862","ControlNumber":"10645","DisclosureBlock":"<b>&nbsp;J. Kaufman, <\/b> <br><b>Heidelberg Pharma AG<\/b> Other, PI. <br><b>M. Raab, <\/b> <br><b>Heidelberg Pharma<\/b> Other, PI. <br><b>S. Richard, <\/b> <br><b>Heidelberg Pharma AG<\/b> Other, PI. <br><b>S. Grosicki, <\/b> <br><b>Heidelberg Pharma AG<\/b> Other, PI. <br><b>I. Takács, <\/b> <br><b>Heidelberg Pharma AG<\/b> Other, PI. <br><b>A. Strassz, <\/b> <br><b>Heidelberg Pharma AG<\/b> Employment, Stock, Stock Option. <br><b>A. Pahl, <\/b> <br><b>Heidelberg Pharma AG<\/b> Employment, Stock, Stock Option. <br><b>M. Kulke, <\/b> <br><b>Heidelberg Pharma AG<\/b> Employment, Stock, Stock Option. <br><b>T. Michael, <\/b> <br><b>Heidelberg Pharma AG<\/b> Employment, Stock Option. <br><b>A. Last, <\/b> <br><b>Heidelberg Pharma AG<\/b> Employment, Stock Option. <br><b>H. Szabóki, <\/b> <br><b>Heidelberg Pharma AG<\/b> Employment, Stock Option. <br><b>G. Jentsch, <\/b> <br><b>BAST GmbH<\/b> Employment. <br><b>Heidelberg Pharma AG<\/b> Independent Contractor. <br><b>O. Schönborn-Kellenberger, <\/b> <br><b>Cogitars GmbH<\/b> Employment. <br><b>Heidelberg Pharma AG<\/b> Independent Contractor. <br><b>R. Orlowski, <\/b> <br><b>Heidelberg Pharma AG<\/b> Other, PI.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11531","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT067","PresenterBiography":null,"PresenterDisplayName":"András Strassz, MD","PresenterKey":"0ded3b30-b7e6-4d74-b029-877e0a9ca0d9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT067. The anti-BCMA antibody-drug conjugate HDP-101 with a novel amanitin payload shows promising initial first in human results in relapsed multiple myeloma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"The anti-BCMA antibody-drug conjugate HDP-101 with a novel amanitin payload shows promising initial first in human results in relapsed multiple myeloma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"Checkpoint Inhibitors,Solid tumors,Myeloid-derived suppressor cells,Antibody,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"E. Y. Yu<sup>1<\/sup>, J. Henry<sup>2<\/sup>, M. R. Patel<sup>3<\/sup>, P. Swiecicki<sup>4<\/sup>, I. Micaily<sup>5<\/sup>, B. Garmezy<sup>6<\/sup>, K. Banda<sup>1<\/sup>, V. Hayreh<sup>7<\/sup>, K. Lustig<sup>7<\/sup>, Y. Ovechkina<sup>7<\/sup>, S. P. Iadonato<sup>7<\/sup>, <b>T. Guillaudeux<\/b><sup>7<\/sup>, L. Rosen<sup>8<\/sup>; <br\/><sup>1<\/sup>Fred Hutchinson Cancer Center, Seattle, WA, <sup>2<\/sup>Sarah Cannon Research Institute, Denver, CO, <sup>3<\/sup>Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, FL, <sup>4<\/sup>University of Michigan, Ann Arbor, MI, <sup>5<\/sup>Thomas Jefferson University, Philadelphia, PA, <sup>6<\/sup>Tennesse Oncology, Nashville, TN, <sup>7<\/sup>Kineta, Seattle, WA, <sup>8<\/sup>UCLA, Santa Monica, CA","CSlideId":"","ControlKey":"49f55ee2-8709-4dd4-ab82-5274af2b3712","ControlNumber":"9570","DisclosureBlock":"<b>&nbsp;E. Y. Yu, <\/b> <br><b>Kineta Inc.<\/b> Independent Contractor. <br><b>J. Henry, <\/b> <br><b>Kineta Inc.<\/b> Grant\/Contract. <br><b>M. R. Patel, <\/b> <br><b>Kineta Inc.<\/b> Grant\/Contract. <br><b>P. Swiecicki, <\/b> <br><b>Kineta Inc.<\/b> Grant\/Contract. <br><b>I. Micaily, <\/b> <br><b>Kineta Inc.<\/b> Grant\/Contract. <br><b>B. Garmezy, <\/b> <br><b>Kineta Inc.<\/b> Grant\/Contract. <br><b>K. Banda, <\/b> <br><b>Kineta Inc.<\/b> Grant\/Contract. <br><b>V. Hayreh, <\/b> <br><b>Kineta Inc.<\/b> Independent Contractor, Stock Option. <br><b>K. Lustig, <\/b> <br><b>Kineta Inc.<\/b> Employment, Stock, Stock Option. <br><b>Y. Ovechkina, <\/b> <br><b>Kineta Inc.<\/b> Employment, Stock Option. <br><b>S. P. Iadonato, <\/b> <br><b>Kineta Inc.<\/b> Employment, Stock, Stock Option, Patent. <br><b>T. Guillaudeux, <\/b> <br><b>Kineta Inc.<\/b> Employment, Stock, Stock Option, Patent. <br><b>L. Rosen, <\/b> <br><b>Kineta Inc.<\/b> Grant\/Contract.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11532","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT068","PresenterBiography":null,"PresenterDisplayName":"Thierry Guillaudeux, PhD","PresenterKey":"68dc7fd2-f119-4649-8501-af2e367a8991","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT068. Interim results of the ongoing phase 1-2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Interim results of the ongoing phase 1-2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"CAR T cells,Cancer immunotherapy,Gastric cancer,Monocyte,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"T. Luo<sup>1<\/sup>, Z. Lu<sup>2<\/sup>, Z. Wu<sup>3<\/sup>, Y. Dong<sup>4<\/sup>, <b>Y. Zhu<\/b><sup>4<\/sup>, M. Feng<sup>4<\/sup>, S. Mei<sup>5<\/sup>, W. Fang<sup>6<\/sup>, D. Zhu<sup>4<\/sup>; <br\/><sup>1<\/sup>The Naval Medical University, Shanghai, China, <sup>2<\/sup>Naval Medical University, Shanghai, China, <sup>3<\/sup>Fudan University, Shanghai, China, <sup>4<\/sup>Department of Pharmacology, School of Basic Medical Science,Fudan University, Shanghai, China, <sup>5<\/sup>Clinical Translational Research Center, Shanghai Pulmonary Hospital, School of Life Science and Technology, Tongji University, Shanghai, China, <sup>6<\/sup>Zhejiang University, Hangzhou, China","CSlideId":"","ControlKey":"b68a16ca-03a4-4912-bc96-818258c80b70","ControlNumber":"10491","DisclosureBlock":"&nbsp;<b>T. Luo, <\/b> None..<br><b>Z. Lu, <\/b> None..<br><b>Z. Wu, <\/b> None..<br><b>Y. Dong, <\/b> None..<br><b>Y. Zhu, <\/b> None..<br><b>M. Feng, <\/b> None..<br><b>S. Mei, <\/b> None..<br><b>W. Fang, <\/b> None..<br><b>D. Zhu, <\/b> None.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11533","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT069","PresenterBiography":null,"PresenterDisplayName":"Yuanyuan Zhu","PresenterKey":"ab186a77-8d98-4b2d-b60c-fba2e4804bc6","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT069. Targeting EpCAM via CAR T-cells is an effective treatment for gastric cancer patients and subsequent toll-like receptor signaling activation in CD36+ monocyte underlies the resulting cytokine release syndrome","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Targeting EpCAM via CAR T-cells is an effective treatment for gastric cancer patients and subsequent toll-like receptor signaling activation in CD36+ monocyte underlies the resulting cytokine release syndrome","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"CAR T cells,allogeneic,lymphodepletion,cyclophosphamide,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Haag<\/b>, J. D. Eskew, K. McArthur, J. McCaigue, S. Vaziri, S. DePrimo, C. E. Martin, C. Gregovics, A. Murphy, H. Namini, E. Christie, M. Marinez-Prieto, R. Belani, S. Cranert, J. Coronella, D. Shedlock; <br\/>Poseida Therapeutics, Inc., San Diego, CA","CSlideId":"","ControlKey":"1b745a1a-4c41-4c99-91f9-e5b83c475ff5","ControlNumber":"10809","DisclosureBlock":"<b>&nbsp;S. Haag, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>J. D. Eskew, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>K. McArthur, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>J. McCaigue, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>S. Vaziri, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>S. DePrimo, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>C. E. Martin, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>C. Gregovics, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>A. Murphy, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>H. Namini, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>E. Christie, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>M. Marinez-Prieto, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>R. Belani, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>S. Cranert, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>J. Coronella, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>D. Shedlock, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option, Patent.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11534","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT070","PresenterBiography":null,"PresenterDisplayName":"Sabrina Haag","PresenterKey":"00cb473c-3ff4-4831-8306-eb8097efa7a4","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT070. Solid tumor patients require higher cyclophosphamide (cy) dose than multiple myeloma (MM) patients to achieve adequate lymphodepletion (LD) necessary to enable allogeneic CAR-T expansion","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Solid tumor patients require higher cyclophosphamide (cy) dose than multiple myeloma (MM) patients to achieve adequate lymphodepletion (LD) necessary to enable allogeneic CAR-T expansion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT04-01 Phase I adult clinical trials,,"},{"Key":"Keywords","Value":"CAR T cells,allogeneic ,BCMA,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>B. Dholaria<\/b><sup>1<\/sup>, L. Shune<sup>2<\/sup>, A. Kin<sup>3<\/sup>, K. McArthur<sup>4<\/sup>, J. D. Eskew<sup>4<\/sup>, C. E. Martin<sup>4<\/sup>, S. Haag<sup>4<\/sup>, J. McCaigue<sup>4<\/sup>, H. Namini<sup>4<\/sup>, S. DePrimo<sup>4<\/sup>, S. Cranert<sup>4<\/sup>, J. Coronella<sup>4<\/sup>, D. Shedlock<sup>4<\/sup>, R. Belani<sup>4<\/sup>; <br\/><sup>1<\/sup>Vanderbilt – Ingram Cancer Center, Nashville, TN, <sup>2<\/sup>University of Kansas Medical Center, Kansas City, MO, <sup>3<\/sup>Karmanos Cancer Center, Detroit, MI, <sup>4<\/sup>Poseida Therapeutics, San Diego, CA","CSlideId":"","ControlKey":"1b93652f-0f33-4f75-a1aa-7d2484427de0","ControlNumber":"10849","DisclosureBlock":"<b>&nbsp;B. Dholaria, <\/b> <br><b>Poseida Therapeutics<\/b> Grant\/Contract. <br><b>L. Shune, <\/b> <br><b>Poseida Therapeutics<\/b> Grant\/Contract. <br><b>A. Kin, <\/b> <br><b>Poseida Therapeutics<\/b> Grant\/Contract. <br><b>K. McArthur, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>J. D. Eskew, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>C. E. Martin, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>S. Haag, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>J. McCaigue, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>H. Namini, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>S. DePrimo, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>S. Cranert, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>J. Coronella, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>D. Shedlock, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option, Patent. <br><b>R. Belani, <\/b> <br><b>Poseida Therapeutics<\/b> Employment, Stock, Stock Option.","End":"4\/8\/2024 12:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11535","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"21","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT071","PresenterBiography":null,"PresenterDisplayName":"Bhagirathbhai Dholaria, MBBS","PresenterKey":"cdeb6325-d595-4472-a6ae-0398038ad442","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT071. Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  9:00AM","SessionId":"613","SessionOnDemand":"False","SessionTitle":"Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 9:00:00 AM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Clinical activity of P-BCMA-ALLO1, a B-cell maturation antigen (BCMA) targeted allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed refractory multiple myeloma (RRMM) patients (pts) following progression on prior BCMA targeting therapy","Topics":null,"cSlideId":""}]